Cell sheet, acellular matrix material and preparation method thereof

By using cell membranes prepared by IMRC cells, the problem of insufficient biological activity of cell membranes in the prior art is solved, the high expression of immune regulatory factors and mechanical properties are improved, and better regenerative medical applications are provided.

CN119060950APending Publication Date: 2024-12-03BEIJING INST FOR STEM CELL & REGENERATIVE MEDICINE +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410694733.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the prior art, the biological activity of cell membranes is insufficient, and hydrogels from heterogeneous tissues have a risk of pathogen carrying, the human tissue source is limited, and individual differences are large, making it difficult to meet the needs of efficient regenerative medicine applications.

Method used

By using cell membranes prepared by immune and stromal regulatory cells (IMRC), the expression of extracellular matrix-related proteins is enhanced, and the expression of high-expression of immune regulation-related factors and nutritional factors are formed, and pro-inflammatory factors are reduced, thereby improving mechanical performance.

Benefits of technology

It has achieved high expression immune regulation and mechanical performance improvement of cell membranes, providing better biological activity and potential for regenerative medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060950A_ABST
    Figure CN119060950A_ABST
Patent Text Reader

Abstract

The invention provides a cell sheet with high expression of immune regulation related factors, nutritional factors and extracellular matrix related proteins and low expression of proinflammatory factors and a preparation method of the cell sheet. The cell sheet has better immune regulation ability and excellent mechanical properties, and fibers are more compact and uniform. The invention also provides an acellular matrix material based on the cell sheet and a composite cell sheet based on the acellular matrix material. The invention also provides application of the cell sheet, the composite cell sheet and the acellular matrix material in regenerative medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of regenerative medicine, and specifically provides a cell membrane sheet that highly expresses immune regulation-related factors, nutritional factors and extracellular matrix-related proteins and lowly expresses pro-inflammatory factors, and a preparation method thereof, a decellularized matrix material based on the cell membrane sheet, and a composite cell membrane sheet based thereon, as well as uses of the cell membrane sheet, the composite cell membrane sheet and the decellularized matrix material in regenerative medicine. Background Art

[0002] The extracellular matrix is ​​a complex network composed of macromolecular substances synthesized and secreted by various tissues and cells in the body, which are distributed and aggregated on the cell surface and intercellular substances. Decellularized matrix refers to the extracellular matrix material after the cell components are removed. As a natural scaffold, it has biological activity, biocompatibility and non-immunogenicity. At the same time, it can retain cell growth factors, enhance the growth, migration, proliferation, differentiation and angiogenesis of seed cells, and is crucial for tissue and organ regeneration and functional repair.

[0003] The application of decellularized matrix in regenerative medicine and tissue engineering has become increasingly common, and because it can take a variety of forms, including membranes, powders and hydrogels, among which hydrogels have strong plasticity and can be used in different ways and combinations, such as as coatings, as cell carriers, as drug carriers such as growth factors, as mixed / modified materials, as bio-inks for tissue 3D printing, etc., it has broad application prospects. At present, most of the research on hydrogels is focused on hydrogels derived from xenogeneic tissues or hydrogels derived from human tissues. Xenogeneic tissues have the risk of carrying pathogens, human tissues are limited, and there are great individual differences between organs. There are relatively few studies on the preparation of hydrogels from cell sources.

[0004] Decellularized matrix hydrogels can be prepared from cell sheets, which are endogenous scaffolds formed by the extracellular matrix secreted by the cells themselves. Although some preparation methods of cell sheets have been reported, there is still a demand in this field for cell sheets with better biological activity. Summary of the invention

[0005] In previous studies, the inventors provided immune and matrix regulatory cells (IMRCs), which have mesenchymal stem cell-like properties but also have a unique gene expression profile different from umbilical cord mesenchymal stem cells (UCMSCs). The inventors unexpectedly found that a cell membrane sheet that secretes more active factors and extracellular matrix-related proteins and has better mechanical properties can be prepared based on the cells, thereby providing the following invention.

[0006] Cell membrane

[0007] In a first aspect, the present invention provides a cell membrane sheet, which is formed by immune and matrix regulatory cells (IMRC) and the extracellular matrix secreted by them, wherein the extracellular matrix at least contains: COL15A1, COL8A1, EFEMP2, FBLN5, MFAP2, MXRA5, PCOLCE, THBS2, LOXL2, TIMP1, CLEC2D, HPX, BGN, and GDF15.

[0008] In certain embodiments, the content of the above protein factors is increased compared to that in a primary mesenchymal stem cell sheet (eg, a UCMSC cell sheet). In certain embodiments, the content of the above protein factors is independently increased by at least about 1.2 times, at least about 1.5 times, at least about 1.8 times, at least about 2 times, at least about 2.5 times, at least about 3 times, at least about 3.5 times, at least about 4 times, at least about 4.5 times, at least about 5 times, at least about 5.5 times, at least about 6 times, at least about 6.5 times, at least about 7 times, at least about 7.5 times, at least about 8 times, at least about 8.5 times, at least about 9 times, at least about 9.5 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 45 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times compared to primary mesenchymal stem cell membrane sheets (e.g., UCMSC cell membrane sheets).

[0009] In certain embodiments, the content of any of the above proteins is determined by protein profiling of a decellularized membrane sheet (ie, a decellularized matrix). In certain embodiments, the cell membrane sheet to be tested is a membrane sheet cultured for 21 days.

[0010] In certain embodiments, the cell sheet has an increased FN expression level, ELN expression level, and / or POSTN expression level compared to a primary mesenchymal stem cell sheet (eg, a UCMSC cell sheet).

[0011] In certain embodiments, the FN expression level of the cell sheet is at least about 5 times, at least about 6 times, for example, about 7 times, compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet). In certain embodiments, the FN expression level is about 5 to 10 times, about 5 to 9 times, about 5 to 8 times, about 6 to 10 times, about 6 to 9 times, or about 6 to 8 times.

[0012] In certain embodiments, the ELN expression level of the cell sheet is at least about 50 times (e.g., at least about 80 times, at least about 90 times, at least about 100 times, at least about 110 times, at least about 120 times, or at least about 130 times; e.g., about 131 times) compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet). In certain embodiments, the ELN expression level is about 100-150 times, about 100-145 times, about 100-140 times, about 100-135 times, about 110-150 times, about 110-145 times, about 110-140 times, about 110-135 times, about 120-150 times, about 120-145 times, about 120-140 times, about 120-135 times, or about 125-135 times.

[0013] In certain embodiments, compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet), the POSTN expression level of the cell sheet is at least about 50 times (e.g., at least about 80 times, at least about 90 times, at least about 100 times, at least about 110 times, at least about 120 times, or at least about 130 times; e.g., about 131.84 times). In certain embodiments, the POSTN expression level is about 100-150 times, about 100-145 times, about 100-140 times, about 100-135 times, about 110-150 times, about 110-145 times, about 110-140 times, about 110-135 times, about 120-150 times, about 120-145 times, about 120-140 times, about 120-135 times, or about 125-135 times.

[0014] In certain embodiments, compared to primary mesenchymal stem cell sheets (e.g., UCMSC cell sheets), the cell sheet has an FN expression level of about 6 to 8 times, an ELN expression level of about 120 to 140 times (e.g., about 120 to 135 times, about 125 to 135 times), and a POSTN expression level of about 120 to 140 times (e.g., about 120 to 135 times, about 125 to 135 times), as compared to primary mesenchymal stem cell sheets (e.g., UCMSC cell sheets).

[0015] In certain embodiments, the expression level of COL1A1 in the cell sheet is at least about 8 times (e.g., at least about 9 times, e.g., about 9.9 times), e.g., about 8-12 times, about 8-11 times, about 8-10 times, about 9-12 times, about 9-11 times, about 9-10 times, compared with that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0016] In certain embodiments, the COL1A2 expression level of the cell sheet is at least about 10 times (e.g., at least about 11 times, at least about 12 times, for example, about 12.98 times), for example, about 10-15 times, about 10-14 times, about 10-13 times, about 11-15 times, about 11-14 times, about 11-13 times, compared with that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0017] In certain embodiments, the COL4A1 expression level of the cell sheet is at least about 5 times (e.g., at least about 6 times, e.g., about 6.74 times), e.g., about 5-10 times, about 5-9 times, about 5-8 times, about 5-7 times, or about 6-7 times, compared to that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0018] In certain embodiments, the TNC expression level of the cell sheet is at least about 18 times (e.g., at least about 19 times, at least about 20 times, or at least about 21 times, for example, about 21.13 times), for example, about 18-25 times, about 18-24 times, about 18-23 times, about 18-22 times, about 19-25 times, about 19-24 times, about 19-23 times, about 19-22 times, about 20-25 times, about 20-24 times, about 20-23 times, about 20-22 times, about 20-25 times, about 20-24 times, about 20-23 times, about 20-22 times.

[0019] In certain embodiments, the COL4A2 expression level of the cell sheet is at least about 8 times (e.g., at least about 9 times, e.g., about 9.54 times), e.g., about 8-12 times, about 8-11 times, about 8-10 times, about 9-12 times, about 9-11 times, about 9-10 times, compared to that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0020] In certain embodiments, the LAMC1 expression level of the cell sheet is at least about 1.1 times (e.g., at least about 1.2 times, e.g., about 1.28 times), e.g., about 1.1-1.5 times, about 1.1-1.4 times, about 1.1-1.3 times, about 1.2-1.5 times, about 1.2-1.4 times, about 1.2-1.3 times, compared with that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0021] In certain embodiments, the CXCL12 expression level of the cell membrane is at least about 1.2 times (e.g., at least about 1.3 times, at least about 1.4 times, for example, about 1.49 times), for example, about 1.2-1.8 times, about 1.2-1.7 times, about 1.2-1.6 times, about 1.2-1.5 times, about 1.3-1.8 times, about 1.3-1.7 times, about 1.3-1.6 times, about 1.3-1.5 times, about 1.3-1.8 times, about 1.3-1.7 times, about 1.3-1.6 times, about 1.3-1.5 times, compared with that of a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0022] In certain embodiments, the cell membrane sheet has one or more characteristics selected from the following compared to a primary mesenchymal stem cell membrane sheet (e.g., a UCMSC cell membrane sheet): (1) the expression level of COL1A1 is about 8 to 12 times (e.g., about 8 to 11 times, about 8 to 10 times, about 9 to 12 times, about 9 to 11 times, about 9 to 10 times); (2) the expression level of COL1A2 is about 11 to 15 times (e.g., about 11 to 14 times, about 11 to 13 times); (3) the expression level of COL4A1 is about 5 to 8 times (e.g., about 5 to 7 times, about 6 to 7 times); (4) the expression level of TNC is about 10 times (e.g., ... (5) the expression level of COL4A2 is about 8 to 12 times (e.g., about 8 to 11 times, about 8 to 10 times, about 9 to 12 times, about 9 to 11 times, about 9 to 10 times); (6) the expression level of LAMC1 is about 1.1 to 1.4 times (e.g., about 1.1 to 1.3 times, about 1.2 to 1.4 times, about 1.2 to 1.3 times); (7) the expression level of CXCL12 is about 1.2 to 1.6 times (e.g., about 1.2 to 1.5 times, about 1.3 to 1.6 times, about 1.3 to 1.5 times).

[0023] In certain embodiments, the expression level described in any of the above embodiments is an mRNA level. In certain embodiments, the mRNA expression level is determined by extracting the total RNA of the cell membrane sheet and performing RT-PCR or single cell RNA sequencing (scRNA-seq). In certain embodiments, the mRNA expression level is determined by RT-PCR using the primer sequences shown in SEQ ID NOs: 1-30.

[0024] In certain embodiments, the cell membrane tested in any of the above embodiments is a membrane cultured for 21 days.

[0025] In certain embodiments, the cell membrane sheet secretes LIF and shows an increase of at least about 300 times (e.g., at least about 350 times, at least about 400 times; e.g., about 437 times) compared to a primary mesenchymal stem cell membrane sheet (e.g., a UCMSC cell membrane sheet), e.g., about 300 to 500 times, about 300 to 450 times, about 350 to 450 times, or about 400 to 450 times. In certain embodiments, the LIF is a protein level. In certain embodiments, the secretion change is determined by the culture supernatant of the cell membrane sheet (e.g., cultured for 21 days). In certain embodiments, the cell membrane sheet tested is a membrane sheet cultured for 21 days.

[0026] In certain embodiments, the LIF content is at least about 100 pg / mL (e.g., at least about 110 pg / mL, at least about 120 pg / mL, at least about 150 pg / mL, at least about 160 pg / mL, at least about 180 pg / mL, or at least about 190 pg / mL; e.g., about 190.19 pg / mL), e.g., about 100-300 pg / mL, about 100-250 pg / mL, about 100-220 pg / mL, about 100-210 pg / mL, about 100-200 pg / mL, about 120 pg / mL, about 130 pg / mL, about 140 pg / mL, about 150 pg / mL, about 160 pg / mL, about 180 pg / mL, or about 190 pg / mL; e.g., about 190.19 pg / mL). 0~300pg / mL, about 120~250pg / mL, about 120~220pg / mL, about 120~210pg / mL, about 120~200pg / mL, about 150~300pg / mL, about 150~250pg / mL, about 150~220pg / mL, about 150~210pg / mL, about 150~200pg / mL, about 180~220pg / mL, about 180~210pg / mL, about 180~200pg / mL, about 185~195pg / mL. In certain embodiments, the secretion amount is measured by the culture supernatant of the cell membrane sheet (e.g., cultured for 21 days). In certain embodiments, the secretion amount is measured using the Bio-Plex 200 suspension chip system.

[0027] In certain embodiments, the cell membrane sheet secretes HGF and shows an increase of at least about 1.1 times (e.g., at least about 1.2 times, e.g., about 1.25 times) compared to a primary mesenchymal stem cell membrane sheet (e.g., a UCMSC cell membrane sheet), e.g., about 1.1 to 1.5 times, about 1.1 to 1.4 times, about 1.1 to 1.3 times, about 1.2 to 1.5 times, about 1.2 to 1.4 times, about 1.2 to 1.3 times. In certain embodiments, the secretion change is determined by the culture supernatant of the cell membrane sheet (e.g., cultured for 21 days). In certain embodiments, the cell membrane sheet tested is a membrane sheet cultured for 21 days.

[0028] In certain embodiments, the HGF content is at least about 100 pg / mL (e.g., at least about 110 pg / mL; e.g., about 111.86 pg / mL), e.g., about 100-120 pg / mL, about 105-120 pg / mL, about 110-120 pg / mL, about 110-115 pg / mL. In certain embodiments, the secretion amount is measured by the culture supernatant of the cell membrane sheet (e.g., cultured for 21 days). In certain embodiments, the secretion amount is measured using the Bio-Plex 200 suspension chip system.

[0029] In certain embodiments, the pro-inflammatory factors secreted by the cell sheet are reduced compared to primary mesenchymal stem cell sheets (eg, UCMSC cell sheets).

[0030] In certain embodiments, the proinflammatory factor is selected from IL6, IL1α, IL1β.

[0031] In certain embodiments, IL6 shows at least about 100-fold (e.g., at least about 110-fold, such as about 114.7-fold) reduction, such as about 100-120-fold, about 110-120-fold reduction, compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet).

[0032] In certain embodiments, IL1α shows at least about 5-fold (e.g., at least about 6-fold, e.g., about 6.16-fold) reduction, e.g., about 5-8-fold, about 5-7-fold, about 6-8-fold, about 6-7-fold reduction, compared to primary mesenchymal stem cell sheets (e.g., UCMSC cell sheets).

[0033] In certain embodiments, IL1β shows at least about 6-fold (e.g., at least about 7-fold, e.g., about 7.16-fold) reduction, e.g., about 6-9-fold, about 6-8-fold, about 7-9-fold, about 7-8-fold reduction, compared to primary mesenchymal stem cell sheets (e.g., UCMSC cell sheets).

[0034] In certain embodiments, the expression level of the pro-inflammatory factor is the mRNA level. Preferably, the total RNA of the cell membrane sheet is extracted and RT-PCR or single cell RNA sequencing (scRNA-seq) is performed. In certain embodiments, the mRNA expression level is determined by RT-PCR using the primer sequences shown in SEQ ID NOs: 1-30. In certain embodiments, the cell membrane sheet tested is a membrane sheet cultured for 21 days.

[0035] In certain embodiments, the cell membrane sheet of the present invention is a sheet-like structure formed by IMRC cells and the extracellular matrix secreted by them.

[0036] In some embodiments, the fiber diameter of the extracellular matrix is ​​less than 0.5 μm, such as 0.2-0.5 μm, 0.2-0.4 μm, 0.3-0.4 μm. In some embodiments, the fiber density of the extracellular matrix is ​​12-16 fibers / 25 μm.

[0037] In certain embodiments, the cell membrane sheet has a Young's modulus of at least 500 Pa, such as at least 800 Pa, at least 1000 Pa, at least 2000 Pa, at least 3000 Pa or at least 3500 Pa.

[0038] In certain embodiments, the cell membrane sheet has a thickness of at least 10 μm, such as at least 30 μm, at least 50 μm, at least 60 μm, at least 70 μm, at least 80 μm, at least 90 μm, or at least 100 μm.

[0039] In certain embodiments, the surface of the cell membrane sheet is smooth and flat.

[0040] As used herein, when referring to a measurable value such as an amount, a percentage, etc., the term "about" is meant to encompass variations of ±10%, ±5%, or ±1% from the measurable value.

[0041] In this article, the term "primary mesenchymal stem cells" refers to mesenchymal stem cells isolated from tissues (such as adipose tissue, umbilical cord, bone marrow or umbilical cord blood) directly taken from the body. Exemplarily, the primary umbilical cord mesenchymal stem cells (UCMSC) described herein can be obtained by the following steps: washing with PBS to remove all residual blood from the umbilical cord; removing arteries and veins; cutting the umbilical cord into about 2 mm in size; transferring the umbilical cord fragments to a culture medium and culturing at 37 ° C in an environment of 5% CO2, the culture medium is supplemented with 5% KOSR, 1% Ultroser G, 1×L-glutamine, 1×NEAA and 5ng / mL bFGF in αMEM. UCMSCs are passaged when they reach ~80% confluence. After 5 cycles of culture, cells are harvested for identification.

[0042] Preparation of cell membrane sheets

[0043] In a second aspect, the present invention provides a method for preparing a cell membrane sheet, comprising: culturing IMRC cells in a culture medium containing vitamin C or a derivative thereof to obtain a cell membrane sheet.

[0044] In certain embodiments, the IMRC cells and the extracellular matrix they secrete are in the form of sheets.

[0045] In certain embodiments, the cell sheet is formed by the IMRC cells and the extracellular matrix secreted by them.

[0046] In certain embodiments, the method further comprises separating the cell sheet from the culture container.

[0047] In certain embodiments, the vitamin C derivative is selected from ascorbic acid 2-glucoside, ascorbyl glucoside, or isoascorbic acid.

[0048] In certain embodiments, IMRC cells are seeded into a matrix-coated culture vessel.

[0049] In certain embodiments, the coating matrix is ​​selected from collagen, gelatin, laminin, fibronectin, or derivatives thereof.

[0050] In certain embodiments, the seeding density of the IMRC cells is 1×10 3 / cm 2~1×10 6 / cm 2 ; For example, 1×10 3 / cm 2 ~1×10 5 / cm 2 , 1×10 3 / cm 2 ~5×10 4 / cm 2 , 5×10 3 / cm 2 ~1×10 5 / cm 2 , 5×10 3 / cm 2 ~5×10 4 / cm 2 , for example 2×10 4 / cm 2 .

[0051] In some embodiments, the content of vitamin C or its derivatives is 1-100 μmol / L, such as 10-100 μmol / L, 10-80 μmol / L, 10-60 μmol / L, 10-50 μmol / L. In some embodiments, the content of vitamin C or its derivatives is 40 μmol / L.

[0052] In certain embodiments, the culture medium for preparing the cell membrane sheet is the same culture medium as that for culturing IMRC cells.

[0053] In certain embodiments, the culture medium is a basal medium supplemented with one or more serum or serum replacements, one or more non-essential amino acids, glutamine or a stabilized dipeptide of L-alanyl-L-glutamine, and one or more growth factors.

[0054] In certain embodiments, the one or more sera or serum replacements comprise KOSR and Ultroser G.

[0055] In certain embodiments, the non-essential amino acid is selected from glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine, and combinations thereof; for example, NEAA.

[0056] In certain embodiments, the basal culture medium is selected from α-MEM, MEM, DMEM, high glucose DMEM, KO-DMEM, and any combination thereof.

[0057] In certain embodiments, the one or more growth factors comprise bFGF and TGF-β; optionally further comprise one or more selected from VEGF, EGF, or PDGF.

[0058] In certain embodiments, the culture medium is a basal medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) KOSR, 1-5mM 1×L-glutamine or stabilized dipeptide of L-alanyl-L-glutamine, 1-100ng / mL bFGF, 1-100ng / mL TGFβ, and the following amino acids at a concentration of 0.1-0.5mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine; the basal medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0059] In certain embodiments, the culture medium may further contain, for example, one or more selected from VEGF, EGF, and PDGF at a concentration of 1-100 ng / mL each.

[0060] In some embodiments, the culture medium is a basic culture medium (such as α-MEM) supplemented with the following substances: 5-30% KOSR, 1-5% Ultroser G, 1-5mM L-glutamine, 0.1-0.5mM NEAA, 1-100ng / mL bFGF and 1-100ng / mL TGF-β. In some embodiments, the content of bFGF and TGF-β is 4-100ng / mL, such as 4-90ng / mL, 4-80ng / mL, 4-60ng / mL, 4-50ng / mL, 4-40ng / mL, 4-30ng / mL, 4-20ng / mL, 4-10ng / mL, 5-90ng / mL, 5-80ng / mL, 5-60ng / mL, 5-50ng / mL, 5-40ng / mL, 5-30ng / mL, 5-20ng / mL, 5-10ng / mL. In certain embodiments, the content of bFGF and TGF-β is 5-100 ng / mL, 4-50 ng / mL, or 5-50 ng / mL.

[0061] In certain embodiments, the culture medium is a basal medium (such as α-MEM) supplemented with 5-20% KOSR, 1-5% Ultroser G, 1-5 mM L-glutamine, 0.1-0.5 mM NEAA, 5-100 ng / mL bFGF, and 5-100 ng / mL TGF-β.

[0062] In certain embodiments, the culture medium is a basal medium (such as α-MEM) supplemented with 5-10% KOSR, 1-5% Ultroser G, 1-5 mM L-glutamine, 0.1-0.5 mM NEAA, 5-10 ng / mL bFGF, and 5-10 ng / mL TGF-β.

[0063] In certain embodiments, the culture medium is a basal medium (such as α-MEM) supplemented with 5% KOSR, 1% Ultroser G, 2 mM L-glutamine, 0.1 mM NEAA, and 5 ng / mL bFGF and 5 ng / mL TGF-β.

[0064] In certain embodiments, the culture is at least 1 day. In certain embodiments, the culture is at least 7 days, such as at least 14 days, such as 14 to 28 days, such as 14 to 21 days. In certain embodiments, the culture is about 21 days.

[0065] In certain embodiments, the cell membrane sheet of the present invention can be cultured for a long time, such as at least 35 days, at least 42 days, or at least 45 days, and still maintain a smooth surface. Therefore, the method of the present invention can provide a membrane sheet with a higher thickness by extending the culture time, for example, culturing for at least about 45 days to obtain a cell membrane sheet with a smooth surface of up to 100 μm in thickness.

[0066] In certain embodiments, the method further comprises: pre-culturing the IMRC cells in a culture medium without the addition of vitamin C or its derivatives, for example, for 1 to 2 days, and then culturing with the addition of vitamin C or its derivatives.

[0067] In a third aspect, the present invention further provides a cell membrane sheet prepared by the method described in the second aspect. In certain embodiments, the cell membrane sheet obtained by the method described in the second aspect is as defined in any embodiment of the first aspect.

[0068] IMRC cells

[0069] IMRC refers to immune-and-matrix-regulatory cell (IMRC), see, for example, Wu, J., Song, D., Li, Z. et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res 30, 794–809 (2020).

[0070] In certain embodiments, the IMRC cells have the following characteristics: ≥90% (e.g., ≥95%, ≥96%, ≥97%, ≥98%, ≥99%, or 100%) of the cells express CD73, CD90, CD105, CD29, HLA-ABC; and ≤1% (e.g., ≤0.5%, ≤0.2%, ≤0.1%, or ≤0.01%) of the cells express CD34, CD45, HLA-DR. In certain embodiments, the IMRC cells are CD34 - / CD45 - / HLA–DR - / CD90 + / CD29 + / CD73 + / CD105 + .

[0071] In certain embodiments, the mRNA expression level of MMPl by IMRC cells is at least about 50-fold higher than that of primary umbilical cord mesenchymal stem cells (UCMSCs).

[0072] In certain embodiments, the surface markers are preferably detected by immunology. In certain embodiments, the mRNA expression levels are preferably determined by RT-PCR.

[0073] In certain embodiments, the IMRC cells have an MMP1 mRNA expression level that is at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times, at least about 150 times, at least about 200 times, at least about 300 times, at least about 400 times, at least about 500 times, at least about 1000 times, at least about 2000 times, at least about 3000 times, at least about 5000 times, at least about 8000 times, at least about 10000 times, or at least about 12000 times higher than that of primary umbilical cord mesenchymal stem cells. In certain embodiments, the IMRC cells have an MMP1 mRNA expression level that is at least about 80 times, at least about 85 times, at least about 90 times, at least about 95 times, at least about 100 times higher than that of primary umbilical cord mesenchymal stem cells. In certain embodiments, the IMRC cells have an MMP1 mRNA expression level that is at least about 100 times higher than that of primary umbilical cord mesenchymal stem cells.

[0074] In certain embodiments, the MMP1 positivity of the IMRC cells is not less than 90%, such as not less than 95%, not less than 98%, or not less than 99%, by single cell RNA sequencing (scRNA-seq). In certain embodiments, the MMP1 positivity of the primary UCMSCs is not higher than 10%, such as not higher than 5%, not higher than 2%, or not higher than 1%.

[0075] In certain embodiments, the IMRC cells show an increase (e.g., at least about a 2-fold increase) in the expression level of at least one (e.g., at least two, at least three, or all) gene selected from the following compared to the expression level of these genes in primary UCMSCs: LIF, VEGFA, GREM1, CDC20. In certain embodiments, the expression level is the mRNA level, which is preferably determined by RT-PCR or RNA-seq.

[0076] In certain embodiments, the IMRC cells show a decrease (e.g., at least about 2-fold decrease) in the expression level of at least one (e.g., at least 2, at least 3, or all) gene selected from the following compared to the expression level of these genes in primary UCMSCs: IL-1B, CXCL8, CCL2, CXCL1. In certain embodiments, the expression level is an mRNA level, which is preferably determined by RT-PCR or RNA-seq.

[0077] In certain embodiments, the IMRCs have the ability to undergo tri-lineage differentiation to form mesenchymal tissues (eg, adipocytes, chondrocytes, and osteoblasts).

[0078] In certain embodiments, the IMRC is generated from embryonic stem cells (eg, human embryonic stem cells) or induced pluripotent stem cells.

[0079] Preparation of IMRC cells

[0080] Detailed teachings on the preparation of IMRC cells have been provided in the art.

[0081] For example, exemplary methods can be found in Wu, J., Song, D., Li, Z. et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res 30, 794–809 (2020). Among them, in order to generate hEBs, hESCs were incubated with 1 mg / mL dispase (Gibco, 17105-04) at 37°C for 5 minutes to disperse into small pieces, and then cultured in KO-DMEM (Gibco, A12861-01) supplemented with 20% KOSR (Gibco, A3020902), 1×L-glutamine (Gibco, A12860-01), 1×NEAA (Gibco, 11140050) and 10 ng / mL bFGF (R&D systems, Minneapolis, MN, USA; 233-FB) to form hEBs. Then, hEBs were transferred to a glass cellulose-coated plate and cultured for another 14 days. During this period, outgrowth of hEBs occurred. The growing cells were separated with Tryple (Gibco, A12859-01) and cultured at 1×10 per square centimeter. 4The cells were passaged at a low cell density of 10 cells in "IMRCs medium", which consists of α-MEM (Gibco, 12561-049) and 5% KOSR, 1% Ultroser G (Pall corporation, New York, NY, USA; 15950-017), 1×L-glutamine, 1×NEAA, 5 ng / mL bFGF and 5 ng / mL TGF-β (Peprotech, 96-100-21-10). After the cells are optionally passaged at least once after reaching 80% confluence in IMRCs medium, the harvested cells are IMRC cells, which show fibroblast morphology, express typical mesenchymal stem cell-specific surface markers, including CD73, CD90, CD105 and CD29, and are negative for typical hematopoietic markers (CD45, CD34, HLA-DR).

[0082] In addition, the inventor's previous patent application CN202010998258.0 also teaches in detail the method for preparing a mesenchymal stem cell population.

[0083] In certain embodiments, the method comprises the following steps:

[0084] (1) culturing stem cells using a first culture medium to form embryoid bodies; wherein the first culture medium is a basal culture medium supplemented with the following substances: one or more serum replacements, one or more non-essential amino acids, glutamine or a stabilized dipeptide of L-alanyl-L-glutamine, and bFGF;

[0085] (2) culturing the embryoid bodies using a second culture medium to induce differentiation into IMRC cells; wherein the second culture medium is a basal culture medium supplemented with the following substances: one or more serum replacements, one or more non-essential amino acids, glutamine or a stabilized dipeptide of L-alanyl-L-glutamine, and one or more growth factors.

[0086] In certain embodiments, step (2) comprises: allowing the embryoid bodies to attach to a culture container and culturing them using a second culture medium.

[0087] As used herein, the term "basal medium" refers to any medium capable of supporting cell growth, typically comprising inorganic salts, vitamins, glucose, a buffer system and essential amino acids, and typically having an osmotic pressure of about 280-330 mOsmol.

[0088] In certain embodiments, the stem cell described in step (1) is a totipotent stem cell or a pluripotent stem cell. In certain embodiments, the pluripotent stem cell is selected from an embryonic stem cell, a haploid stem cell, an induced pluripotent stem cell, or an adult stem cell. In certain embodiments, the pluripotent stem cell is an embryonic stem cell, such as a human embryonic stem cell. In certain embodiments, the pluripotent stem cell is an induced pluripotent stem cell.

[0089] In certain embodiments, the first culture medium has one or more of the following characteristics:

[0090] (i) the total content of the one or more serum replacements is 3-30% (v / v), such as about 3% (v / v), about 5% (v / v), about 8% (v / v), about 10% (v / v), about 12% (v / v), about 15% (v / v), about 18% (v / v), about 20% (v / v), about 22% (v / v), about 25% (v / v), about 28% (v / v) or about 30% (v / v);

[0091] (ii) the one or more non-essential amino acids are each contained in an amount of 0.1-0.5 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM or about 0.5 mM;

[0092] (iii) the content of the stabilized dipeptide of glutamine or L-alanyl-L-glutamine is 1-5 mM, such as about 1 mM, about 2 mM, about 3 mM, about 4 mM, or about 5 mM;

[0093] (iv) the content of bFGF is 1-100 ng / mL, such as 2-100 ng / mL, 2-50 ng / mL, 5-100 ng / mL, 5-50 ng / mL, or 5-20 ng / mL; for example, about 1 ng / mL, about 2 ng / mL, about 3 ng / mL, about 5 ng / mL, about 8 ng / mL, about 10 ng / mL, about 15 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 55 ng / mL, about 60 ng / mL, about 65 ng / mL, about 70 ng / mL, about 75 ng / mL, about 80 ng / mL, about 85 ng / mL, about 90 ng / mL, about 95 ng / mL, or about 100 ng / mL.

[0094] In certain embodiments, the first culture medium has one or more of the following characteristics:

[0095] (a) The serum substitute is selected from KOSR, MSC serum-free supplement, UltroserTM G and any combination thereof; Preferably, the serum replacement is KnockOut TM SR (e.g., Thermo: Catalog No. 10828028) (hereinafter referred to as KOSR);

[0096] (b) the non-essential amino acids are selected from the group consisting of glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine, and combinations thereof;

[0097] (c) the basal medium is selected from KnockOut TM DMEM (e.g., Gibco: Catalog No. 10829018) (hereinafter referred to as KO-DMEM), KnockOut TM DMEM / F-12 (e.g., Gibco: Catalog No. 12660-012) (hereinafter referred to as KO-DMEM / F12), DMEM, α-MEM, F-12, MEM, BME, RPMI 1640, G-MEM and any combination thereof; preferably, the basal medium is selected from KO-DMEM, KO-DMEM / F12, DMEM, DMEM / F12; preferably, the basal medium is KO-DMEM.

[0098] In certain embodiments, the first culture medium comprises: 3-30% (v / v) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 1-100 ng / mL bFGF, and the following amino acids at a concentration of 0.1-0.5 mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine.

[0099] In certain embodiments, the first culture medium comprises: 3-30% (v / v) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 1-20 ng / mL bFGF, and the following amino acids at a concentration of 0.1-0.5 mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; preferably, the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, DMEM, DMEM / F12.

[0100] In certain embodiments, the first culture medium comprises: 3-30% (v / v) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 5-20 ng / mL bFGF, and the following amino acids at a concentration of 0.1-0.5 mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; preferably, the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, DMEM, DMEM / F12.

[0101] In certain embodiments, the first culture medium comprises: 5-20% (v / v) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 5-20 ng / mL bFGF, and the following amino acids at a concentration of 0.1-0.5 mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; preferably, the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, DMEM, DMEM / F12.

[0102] In certain embodiments, the first culture medium further comprises β-mercaptoethanol. In certain embodiments, the content of β-mercaptoethanol is 0.1-0.5% (v / v), such as about 0.1% (v / v), about 0.2% (v / v), about 0.3% (v / v), about 0.4% (v / v) or about 0.5% (v / v).

[0103] In certain embodiments, the first culture medium comprises: about 8-12% (v / v) KOSR, about 1-5% (v / v) NEAA (i.e., 0.1-0.5 mM), about 0.5-2.5% (v / v) GlutaMAX (i.e., 1-5 mM), about 5-10 ng / mL bFGF, and preferably also comprises about 0.1% (v / v) β-mercaptoethanol.

[0104] In certain exemplary embodiments, the first culture medium comprises: about 10% (v / v) KOSR, about 1% (v / v) NEAA (i.e., 0.1 mM), about 1% (v / v) GlutaMAX (i.e., 2 mM), about 8 ng / mL bFGF, and preferably also comprises about 0.1% (v / v) β-mercaptoethanol.

[0105] In certain embodiments, the second culture medium has one or more of the following characteristics:

[0106] (i) the total content of the one or more serum replacements is 1-40% (v / v), for example, 1-35% (v / v), 1-30% (v / v), 2-30% (v / v), 5-30% (v / v), 1-20% (v / v), 2-20% (v / v), 5-20% (v / v), 1-10% (v / v), 2-10% (v / v), or 5-10% (v / v). / v); for example, about 1% (v / v), about 2% (v / v), about 3% (v / v), about 5% (v / v), about 8% (v / v), about 10% (v / v), about 12% (v / v), about 15% (v / v), about 18% (v / v), about 20% (v / v), about 22% (v / v), about 25% (v / v), about 28% (v / v), or about 30% (v / v);

[0107] (ii) the one or more non-essential amino acids are each present in an amount of 0.1-0.5 mM, such as 0.1-0.2 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM or about 0.5 mM;

[0108] (iii) the content of the stabilized dipeptide of glutamine or L-alanyl-L-glutamine is 1-5 mM, such as 1-3 mM, such as about 1 mM, about 2 mM, about 3 mM, about 4 mM or about 5 mM;

[0109] (iv) the one or more growth factors are each present in an amount of 1-100 ng / mL, for example, about 1 ng / mL, about 2 ng / mL, about 3 ng / mL, about 4 ng / mL, about 5 ng / mL, about 8 ng / mL, about 10 ng / mL, about 15 ng / mL, about 20 ng / mL, about 25 ng / mL, about 30 ng / mL, about 35 ng / mL, about 40 ng / mL, about 45 ng / mL, about 50 ng / mL, about 55 ng / mL, about 60 ng / mL, about 65 ng / mL, about 70 ng / mL, about 75 ng / mL, about 80 ng / mL, about 85 ng / mL, about 90 ng / mL, about 95 ng / mL, or about 100 ng / mL.

[0110] In certain embodiments, the second culture medium has one or more of the following characteristics:

[0111] (a) The serum substitute is selected from KOSR, MSC serum-free supplement, Ultroser TM G and any combination thereof;

[0112] (b) the non-essential amino acids are selected from the group consisting of glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine, and combinations thereof;

[0113] (c) the basal medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, F12, MEM, BME, RPMI1640, G-MEM and any combination thereof; preferably, the basal medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0114] In certain embodiments, the growth factors comprise bFGF and TGFβ.In certain embodiments, the growth factors comprise 1-100 ng / mL bFGF and 1-100 ng / mL TGFβ.

[0115] In certain embodiments, the bFGF content is 4-100 ng / mL, such as 4-90 ng / mL, 4-80 ng / mL, 4-60 ng / mL, 4-50 ng / mL, 4-40 ng / mL, 4-30 ng / mL, 4-20 ng / mL, 4-10 ng / mL, 5-90 ng / mL, 5-80 ng / mL, 5-60 ng / mL, 5-50 ng / mL, 5-40 ng / mL, 5-30 ng / mL, 5-20 ng / mL, 5-10 ng / mL. In certain embodiments, the bFGF content is 5-100 ng / mL, 10-100 ng / mL.

[0116] In certain embodiments, the TGF-β content is 4-100 ng / mL, for example 4-90 ng / mL, 4-80 ng / mL, 4-60 ng / mL, 4-50 ng / mL, 4-40 ng / mL, 4-30 ng / mL, 4-20 ng / mL, 4-10 ng / mL.

[0117] In certain embodiments, the growth factors include 10-100 ng / mL bFGF and 4-100 ng / mL TGFβ. In certain embodiments, the growth factors further include one or more selected from VEGF, EGF, and PDGF at a concentration of 1-100 ng / mL.

[0118] In certain embodiments, the serum replacement is KOSR, and a serum-free supplement selected from MSC (eg, TBD: Catalog No. SC2013-GB) and Ultroser TMG (e.g., PALL: Product No. 15950-017) (hereinafter referred to as Ultroser G). In certain embodiments, the volume ratio of KOSR to MSC serum-free additive or Ultroser G is 2: 1 to 150: 1, such as about 2: 1, about 3: 1, about 4: 1, about 5: 1, about 6: 1, about 7: 1, about 8: 1, about 9: 1, about 10: 1, about 20: 1, about 50: 1, about 80: 1, about 100: 1, about 120: 1, or about 150: 1. In certain embodiments, the volume ratio of KOSR to MSC serum-free additive or Ultroser G is 10: 1 to 1: 2, such as about 10: 1, about 9: 1, about 8: 1, about 7: 1, about 6: 1, about 5: 1, about 4: 1, about 3: 1, about 2: 1, about 1: 1 or about 1: 2.

[0119] In certain embodiments, the content of KOSR is about 1-30% (v / v), about 1-20% (v / v), about 1-10% (v / v), about 2-10% (v / v), or about 5-10% (v / v). In certain embodiments, the content of MSC serum-free supplement or Ultroser G is about 1-10% (v / v), or about 1-5% (v / v).

[0120] In certain embodiments, the one or more serum or serum replacements comprise KOSR and Ultroser G. In certain embodiments, the second culture medium comprises 1-5% (v / v) Ultroser G, 5-30% (v / v) KOSR.

[0121] In certain embodiments, the second culture medium further comprises ascorbic acid. In certain embodiments, the content of ascorbic acid is 1-100 μg / mL, such as 1-50 μg / mL, 1-20 μg / mL or 5-20 μg / mL.

[0122] In certain embodiments, the second culture medium is a basal culture medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) (such as 4-20% (v / v)) KOSR, 1-5mM stabilized dipeptide of L-alanyl-L-glutamine, 1-100ng / mL bFGF, 1-100ng / mL TGFβ, and the following amino acids each at a concentration of 0.1-0.5mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0123] In certain embodiments, the second culture medium is a basal culture medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) (such as 4-20% (v / v)) KOSR, 1-5mM stabilized dipeptide of L-alanyl-L-glutamine, 4-100ng / mL bFGF, 4-100ng / mL TGFβ, and the following amino acids each at a concentration of 0.1-0.5mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0124] In certain embodiments, the second culture medium is a basal culture medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) (such as 4-20% (v / v)) KOSR, 1-5mM stabilized dipeptide of L-alanyl-L-glutamine, 10-100ng / mL bFGF, 4-100ng / mL TGFβ, and the following amino acids each at a concentration of 0.1-0.5mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamate, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0125] In certain embodiments, the second culture medium may further comprise 1-50 μg / mL ascorbic acid.

[0126] In certain embodiments, the second culture medium may further comprise one or more selected from VEGF, EGF, and PDGF, for example, each at a concentration of 1-100 ng / mL.

[0127] In certain embodiments, the method comprises the following steps:

[0128] (1) using a first culture medium to culture stem cells to form embryoid bodies, wherein the stem cells are embryonic stem cells or induced pluripotent stem cells; wherein the first culture medium is a basal culture medium supplemented with the following substances: one or more serum replacements, one or more non-essential amino acids, glutamine or a stabilized dipeptide of L-alanyl-L-glutamine, and bFGF;

[0129] (2) culturing the embryoid bodies using a second culture medium to induce differentiation into mesenchymal stem cells; wherein the second culture medium is a basal culture medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) (such as 4-20% (v / v)) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 10-100 ng / mL bFGF, 4-100 ng / mL TGFβ, 1-50 μg / mL ascorbic acid, and the following amino acids each at a concentration of 0.1-0.5 mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0130] In certain embodiments, the method comprises the following steps:

[0131] (1) using a first culture medium to culture stem cells to form embryoid bodies, wherein the stem cells are embryonic stem cells or induced pluripotent stem cells; wherein the first culture medium is a basal culture medium supplemented with the following substances: 3-30% (v / v) (e.g., 5-20% (v / v)) of KOSR, 1-5 mM of a stabilized dipeptide of L-alanyl-L-glutamine, 1-100 ng / mL (e.g., 5-20 ng / mL, 5-10 ng / mL) of bFGF, and the following amino acids each at a concentration of 0.1-0.5 mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, DMEM, DMEM / F12;

[0132] (2) culturing the embryoid bodies using a second culture medium to induce differentiation into mesenchymal stem cells; wherein the second culture medium is a basal culture medium supplemented with the following substances: 1-5% (v / v) Ultroser G, 5-30% (v / v) (such as 4-20% (v / v)) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 10-100 ng / mL bFGF, 4-100 ng / mL TGFβ, 1-50 μg / mL ascorbic acid, and the following amino acids each at a concentration of 0.1-0.5 mM: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine; the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

[0133] In certain embodiments, the components contained in the first culture medium and the second culture medium are all cell therapy grade (CTS grade). In certain embodiments, the basal culture medium (such as KO-DMEM), serum replacement (such as KOSR), and stabilized dipeptide of L-alanyl-L-glutamine contained in the first culture medium and the second culture medium are all cell therapy grade (CTS grade).

[0134] In certain embodiments, the step (1) comprises culturing the pluripotent stem cells in a low attachment cell culture dish.

[0135] As used herein, the term "low-attachment cell culture dish" refers to a dish having a coating on the surface that prevents protein adsorption on the dish surface, thereby minimizing the adhesion of monolayer cells to the culture container. Such cell culture dishes are well known to those skilled in the art, including but not limited to Corning's low-attachment dish (Cat. No. 3262).

[0136] In certain embodiments, the duration of culturing in step (1) is 3-14 days, such as about 3 days, about 4 days, about 5 days, about 7 days, about 10 days, or about 14 days.

[0137] In certain embodiments, the duration of culturing in step (1) is 4-7 days, such as about 5 days.

[0138] In certain embodiments, step (2) comprises: 2 The embryoid bodies of step (1) are inoculated into the culture container at a density of.

[0139] In certain embodiments, the step (2) comprises culturing the embryoid bodies in a culture dish coated with gelatin, type I collagen, type IV collagen, vitronectin, fibronectin or poly-lysine.

[0140] In certain embodiments, the step (2) comprises culturing the embryoid bodies in a culture dish coated with vitronectin.

[0141] In certain embodiments, the duration of culturing in step (2) is 10-21 days, such as about 10 days, about 14 days, or about 21 days.

[0142] In certain embodiments, the duration of culturing in step (2) is 10-14 days, such as about 14 days.

[0143] In certain embodiments, step (2) comprises replacing the second culture medium with fresh medium every day or every 1-7 days (e.g., every 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days). In certain embodiments, step (2) comprises discarding the spent media and replacing the second culture medium with fresh medium every day or every 1-7 days (e.g., every 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days).

[0144] In certain embodiments, in steps (1)-(2), the culture conditions are 37°C, 5% CO 2 . In certain embodiments, in steps (1)-(2), the culture is performed in an incubator at 37°C, 5% CO 2 .

[0145] In certain embodiments, the cells attached to the culture container in step (2) are IMRC cells of generation P0. In certain embodiments, when the confluence of the cells attached to the culture container in step (2) is not less than about 80% (e.g., not less than about 85%, not less than about 90%, or not less than about 95%), the cells can be separated from the culture container to obtain IMRC cells of generation P0.

[0146] Therefore, in certain embodiments, the method further comprises: (3) isolating the cells attached to the culture container in step (2), thereby obtaining IMRC cells.

[0147] In certain embodiments, the method further comprises passaging the IMRC cells of step (3).

[0148] In certain embodiments, the cells are passaged when the confluence of the cells is greater than or equal to about 80% (eg, greater than or equal to about 85%, greater than or equal to about 90%, or greater than or equal to about 95%).

[0149] In certain embodiments, the IMRC cells are passaged 1, 2, 3, 4, or 5 times.

[0150] Methods for subculturing cells are well known to those skilled in the art. For example, the method may include: separating cells from a culture container and evenly dispersing the cells in a culture medium, and then inoculating the cells in a culture container. Adding an appropriate amount of culture medium, replacing an appropriate amount of fresh culture medium at regular intervals (e.g., every 1 to 5 days) according to the growth state of the cells, and repeating the subculturing operation when the cells grow to 70 to 100% confluence. Each time the cells are subcultured, the number of generations increases by 1.

[0151] In certain embodiments, the passaging comprises at about 5×10 3 -5×10 4 / cm 2(For example, about 5×10 3 / cm 2 , about 1×10 4 / cm 2 , about 2×10 4 / cm 2 , about 3×10 4 / cm 2 , about 4×10 4 / cm 2 , or about 5×10 4 / cm 2 ) for passage.

[0152] In certain embodiments, the passaging comprises inoculating the cells into the second culture medium for culturing.

[0153] In certain embodiments, the separation comprises disrupting the attachment of the IMRC cells to the culture vessel by: (i) contacting the culture with one or more enzymes selected from the group consisting of trypsin or its analogs, collagenase, dispase, papain, a mixture of collagenase and dispase, and a mixture of collagenase and trypsin or its analogs; (ii) mechanical separation using a cell scraper or the like; or, (iii) contacting the culture with EDTA or EGTA.

[0154] In certain embodiments, the separating comprises disrupting the attachment of the IMRC cells to the culture vessel by enzymatic digestion.

[0155] In certain embodiments, the enzyme is trypsin (eg, Gibco: Cat. No. 25200072).

[0156] Optionally, after obtaining IMRC cells through culture, the cell growth curve can be measured by MTT method, WST method, DNA content detection method, ATP detection method, etc. to evaluate the growth activity of umbilical cord IMRC cells. In addition, the isolated and cultured IMRC cells can be identified by detecting cell surface markers by flow cytometry, three-way differentiation assay, and cell expression genes by PCR.

[0157] In certain embodiments, the medium used to culture the IMRC cells is the second medium.

[0158] Acellular matrix materials

[0159] In a fourth aspect, the present invention provides a decellularized matrix material, which is obtained by decellularizing the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect.

[0160] In certain embodiments, the decellularization treatment comprises physical methods (e.g., temperature, pressure, electroporation, and direct effects of force), chemical methods (e.g., acids and bases, detergents, hypotonic and hypertonic solutions, alcohols and solvents), biological methods (such as enzymes, nucleases, and chelators), or any combination thereof.

[0161] In certain embodiments, the decellularized matrix material is a decellularized membrane sheet, which is a direct product obtained by decellularizing the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect.

[0162] In certain embodiments, the decellularized matrix material is a decellularized hydrogel, which is a product obtained by subjecting the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect to decellularization and digestion treatment.

[0163] In certain embodiments, the digestion treatment comprises the use of an acid (eg, acetic acid or hydrochloric acid) and / or a digestive enzyme (eg, pepsin or trypsin).

[0164] Preparation of decellularized matrix materials

[0165] In a fifth aspect, the present invention provides a method for preparing a cell-free matrix material, comprising:

[0166] (1) providing the cell membrane sheet according to the first aspect of claim 1 or the cell membrane sheet according to the third aspect of claim 3;

[0167] (2) Decellularizing the cell membrane sheet.

[0168] Decellularization is well known to those skilled in the art, see, for example, Kim BS, Das S, Jang J, Cho DW. Decellularized Extracellular Matrix-based Bioinks for Engineering Tissue-and Organ-specific Microenvironments. Chem Rev. 2020; 120(19): 10608-10661. In certain embodiments, the decellularization comprises physical methods (e.g., direct effects of temperature, pressure, electroporation, and force), chemical methods (e.g., acids and alkalis, detergents, hypotonic and hypertonic solutions, alcohols and solvents), biological methods (e.g., enzymes, nucleases, and chelating agents), or any combination thereof.

[0169] In certain embodiments, the decellularization treatment comprises the use of a surfactant (eg, a nonionic surfactant or an ionic surfactant, such as Triton-X 100, sodium dodecyl sulfate (SDS), sodium deoxycholate (SD)).

[0170] In certain embodiments, the decellularization process comprises freeze-thaw, such as multiple freeze-thaw cycles.

[0171] In certain embodiments, the decellularization treatment comprises using 1% Triton-X 100, such as 1% Triton-X100 and 20 mM NH 3 ·H 2 O.

[0172] In certain embodiments, the decellularization treatment comprises using 0.1% SDS.

[0173] In certain embodiments, the product obtained in step (2) is a decellularized membrane sheet.

[0174] In certain embodiments, the decellularized matrix material is a hydrogel, and the method further comprises subjecting the decellularized product to a digestion process.

[0175] Digestion treatment is well known to those skilled in the art, and can be seen, for example, in Kim BS, Das S, Jang J, Cho DW. Decellularized Extracellular Matrix-based Bioinks for Engineering Tissue-and Organ-specific Microenvironments. Chem Rev. 2020; 120(19): 10608-10661.

[0176] In certain embodiments, the digestion treatment comprises the use of an acid (eg, acetic acid or hydrochloric acid) and / or a digestive enzyme (eg, pepsin or trypsin).

[0177] In certain embodiments, the digestion treatment comprises using acetic acid and pepsin. Exemplarily, 0.5 M acetic acid and 10 mg pepsin can be used.

[0178] In certain embodiments, the digestion treatment further comprises the steps of dialysis, freeze drying, and re-dissolution. In certain embodiments, the dissolution comprises using a PBS solution (eg, pH 7-9, such as pH 8).

[0179] Composite cell membrane and its preparation

[0180] In a sixth aspect, the present invention provides a composite cell membrane sheet comprising IMRC cells and at least one cell selected from the following: fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelial cells, and retinal pigment epithelial cells.

[0181] In certain embodiments, the composite cell membrane sheet comprises at least two stacked cell membrane sheets, wherein at least one cell membrane sheet is the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect.

[0182] In certain embodiments, at least one cell membrane sheet in the stacked cell membrane sheets is a cell membrane sheet formed by cells selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells and pericytes), corneal endothelial cells, and retinal pigment epithelial cells.

[0183] In certain embodiments, adhesives are included between the stacked cell membrane sheets.

[0184] In certain embodiments, the adhesive is made of a material that is biocompatible and degradable in the body.

[0185] In certain embodiments, the adhesive is the acellular matrix material described in the fourth aspect.

[0186] In certain embodiments, the adhesive comprises a synthetic biomaterial selected from the following: polyethylene glycol, polyethylene glycol derivatives, polylactic acid, polylactic acid alcohol copolymers, polyanhydrides, polyesters, polyamino acids, polyethylene oxides, polyesters, polymethyl methacrylates, polycarbonates, polyurethanes, polycaprolactones, polyhydroxyalkanoates, polysiloxanes, polyethylene, polyvinyl chloride, polytetrafluoroethylene, polystyrene, polypropylene, N-(3-aminopropyl)methacrylamide hydrochloride (APMA), N-[tris(hydroxymethyl)methyl]acrylamide (THMA), maleic anhydride graft copolymers, polyacrylamide, polyacetal, polypyrrole or any combination thereof. Preferably, the synthetic material is N-(3-aminopropyl)methacrylamide hydrochloride (APMA) and N-[tris(hydroxymethyl)methyl]acrylamide (THMA).

[0187] In certain embodiments, the adhesive comprises a natural biological material selected from the following: natural protein, collagen and collagen derivatives, gelatin and gelatin derivatives, agar and agar derivatives, proteoglycan, alginate and alginate derivatives, matrix glue, propolis, cellulose and cellulose derivatives, chitin and chitosan derivatives, silk protein and its derivatives, laminin and its derivatives, fibronectin and its derivatives, sodium hyaluronate and hyaluronic acid derivatives, agarose and its derivatives, dextran and its derivatives, sucrose and sucrose derivatives, starch, chitosan and chitosan derivatives or any combination thereof, preferably gelatin and gelatin derivatives, chitosan and chitosan derivatives.

[0188] In another aspect, the present invention provides a method for preparing a composite cell membrane sheet, comprising:

[0189] (1) providing a plurality of cell membrane sheets, at least one of which is the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect;

[0190] (2) disposing an adhesive on one of the cell membrane sheets, and then laminating another cell membrane sheet thereon;

[0191] (3) Repeating step (2);

[0192] (4) A stacked product having a predetermined number of sheets is obtained.

[0193] In certain embodiments, at least one cell sheet is a cell sheet formed by cells selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelial cells, and retinal pigment epithelial cells.

[0194] In certain embodiments, the adhesive is made of a material that is biocompatible and degradable in the human body.

[0195] In certain embodiments, the adhesive is the acellular matrix material described in the fourth aspect.

[0196] In certain embodiments, the adhesive comprises a synthetic biomaterial selected from the following: polyethylene glycol, polyethylene glycol derivatives, polylactic acid, polylactic acid alcohol copolymers, polyanhydrides, polyesters, polyamino acids, polyethylene oxides, polyesters, polymethyl methacrylates, polycarbonates, polyurethanes, polycaprolactones, polyhydroxyalkanoates, polysiloxanes, polyethylene, polyvinyl chloride, polytetrafluoroethylene, polystyrene, polypropylene, N-(3-aminopropyl)methacrylamide hydrochloride (APMA), N-[tris(hydroxymethyl)methyl]acrylamide (THMA), maleic anhydride graft copolymers, polyacrylamide, polyacetal, polypyrrole or any combination thereof. Preferably, the synthetic material is N-(3-aminopropyl)methacrylamide hydrochloride (APMA) and N-[tris(hydroxymethyl)methyl]acrylamide (THMA).

[0197] In certain embodiments, the adhesive comprises a natural biological material selected from the following: natural protein, collagen and collagen derivatives, gelatin and gelatin derivatives, agar and agar derivatives, proteoglycan, alginate and alginate derivatives, matrix glue, propolis, cellulose and cellulose derivatives, chitin and chitosan derivatives, silk protein and its derivatives, laminin and its derivatives, fibronectin and its derivatives, sodium hyaluronate and hyaluronic acid derivatives, agarose and its derivatives, dextran and its derivatives, sucrose and sucrose derivatives, starch, chitosan and chitosan derivatives or any combination thereof, preferably gelatin and gelatin derivatives, chitosan and chitosan derivatives.

[0198] In a seventh aspect, the present invention provides a composite cell membrane sheet comprising at least two stacked cell membrane sheets, wherein adhesive is contained between each stacked cell membrane sheet, and the adhesive is selected from the decellularized matrix material described in the fourth aspect.

[0199] In certain embodiments, the at least two layers of cell membrane sheets are each independently formed by cells selected from the following: fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, and retinal pigment epithelial cells.

[0200] In certain embodiments, the composite cell sheet comprises a fibroblast sheet and a keratinocyte sheet.

[0201] In another aspect, a method for preparing a composite cell membrane sheet is provided, comprising:

[0202] (1) Providing multiple cell membrane sheets;

[0203] (2) disposing an adhesive on one of the cell membrane sheets, and then stacking another cell membrane sheet thereon; wherein the adhesive is selected from the decellularized matrix material described in the fourth aspect;

[0204] (3) Repeating step (2);

[0205] (4) A stacked product having a predetermined number of sheets is obtained.

[0206] In certain embodiments, the plurality of cell membrane sheets are each independently formed by cells selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, and retinal pigment epithelial cells.

[0207] In certain embodiments, the plurality of cell sheets comprises fibroblast sheets and keratinocyte sheets.

[0208] In another aspect, the use of the decellularized matrix material of the present invention as an adhesive is provided. Preferably, the adhesive is used to prepare a cell membrane sheet. Preferably, the adhesive is used to prepare the composite cell membrane sheet described in the sixth or seventh aspect.

[0209] Induced differentiation cell sheets and preparation

[0210] In an eighth aspect, the present invention provides an induced differentiated cell sheet, which is obtained by induced differentiation of the cell sheet described in the first aspect or the cell sheet described in the third aspect. Stem cell induced differentiation technology is well known to those skilled in the art, and those skilled in the art can select appropriate induced differentiation conditions according to the target differentiated cell type, thereby obtaining the corresponding induced differentiated cell sheet.

[0211] In certain embodiments, the cell sheet induced to differentiate is an ectoderm tissue sheet (eg, a neural crest cell sheet, a neural cell sheet, a retinal pigment epithelial cell sheet, a keratinocyte epithelial cell sheet).

[0212] In certain embodiments, the induced differentiated cell sheet is a mesodermal tissue sheet (eg, a chondrocyte sheet, a bone cell sheet, a fat cell sheet, a cardiomyocyte sheet, a muscle cell sheet, a vascular endothelial cell sheet, a kidney cell sheet).

[0213] In certain embodiments, the induced differentiated cell sheet is an endoderm tissue sheet (hepatocyte sheet, pancreatic β cell sheet, intestinal cell sheet, gastric cell sheet).

[0214] In certain embodiments, the cell sheet induced to differentiate is a chondrocyte sheet.

[0215] On the other hand, a method for preparing the above-mentioned differentiated cell sheet is provided, comprising:

[0216] (1) Providing the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect;

[0217] (2) Cultivating the cell sheet under conditions that induce differentiation, for example, culturing in a culture medium supplemented with induction factors.

[0218] In certain embodiments, the method comprises: culturing IMRC cells using the method described in the second aspect, and replacing the culture medium with a culture medium supplemented with an induction factor on day 5 to 10 of culture (e.g., day 5 to 9, day 5 to 8, day 6 to 10, day 6 to 9, day 6 to 8, e.g., day 7) and continuing to culture (e.g., for at least 7 days, at least 14 days).

[0219] Medical Applications

[0220] On the other hand, a pharmaceutical composition is provided, which comprises the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect, the decellularized matrix material described in the fourth aspect, or the composite cell membrane sheet described in the sixth aspect or the seventh aspect, or the induced differentiated cell membrane sheet described in the eighth aspect, and a pharmaceutically acceptable carrier and / or excipient.

[0221] On the other hand, provided is the use of the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect, the decellularized matrix material described in the fourth aspect, the composite cell membrane sheet described in the sixth aspect or the seventh aspect, the induced differentiated cell membrane sheet described in the eighth aspect, or the pharmaceutical composition described herein in the preparation of a drug for regeneration or repair of tissues or organs.

[0222] On the other hand, provided is the use of the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect, the decellularized matrix material described in the fourth aspect, the composite cell membrane sheet described in the sixth aspect or the seventh aspect, the induced differentiated cell membrane sheet described in the eighth aspect, or the pharmaceutical composition described herein, in the preparation of a drug for treating tissue or organ damage.

[0223] In certain embodiments, the tissue or organ damage includes corneal damage (e.g., corneal alkali burns), skin damage (e.g., skin burns, skin scalds, diabetic foot), heart disease (e.g., myocardial damage), bone damage (e.g., skull damage, bone defects), endometrial damage (e.g., intrauterine adhesions), meniscus damage, and / or muscle damage, periodontal damage (e.g., periodontitis), esophagus (e.g., esophageal mucosal damage), liver damage (e.g., cirrhosis), pancreatic disease (e.g., diabetes, pancreatitis), lung disease (e.g., lung damage, pulmonary fibrosis).

[0224] In certain embodiments, the cell sheet is differentiated into osteoblasts or chondrocytes.

[0225] On the other hand, the cell membrane sheet described in the first aspect or the cell membrane sheet described in the third aspect, the decellularized matrix material described in the fourth aspect, or the composite cell membrane sheet described in the sixth aspect or the seventh aspect, or the cell membrane sheet induced to differentiate described in the eighth aspect, or the pharmaceutical composition described herein, are provided for use in preparing a drug for cell, tissue or organ transplantation. In certain embodiments, the decellularized hydrogel described herein is used to prepare a drug for cell, tissue or organ transplantation as an excipient in the drug.

[0226] In another aspect, the use of the decellularized matrix material of the present invention as a pharmaceutically acceptable carrier and / or excipient in a drug is provided. In certain embodiments, the drug comprises a nucleic acid drug, a small molecule drug, a protein drug, and / or a cell, tissue or organ transplant drug.

[0227] On the other hand, the acellular matrix material of the present invention is provided for use in cell culture (e.g., culture of pluripotent stem cells, differentiation of pluripotent stem cells), organoid culture, or 3D printing. In certain embodiments, the acellular matrix material is used as ink for 3D printing. In certain embodiments, the acellular matrix material is used as a coating matrix for cell culture or organoid culture.

[0228] On the other hand, a method for culturing cells or organoids in vitro is provided, comprising culturing in the presence of the acellular matrix material of the fourth aspect. In certain embodiments, the acellular matrix material is a hydrogel. In certain embodiments, the method comprises culturing on a surface coated with the hydrogel.

[0229] In another aspect, a 3D printing method is provided, which comprises using the decellularized matrix material of the fourth aspect as ink. Preferably, the decellularized matrix material is a hydrogel.

[0230] Beneficial Effects

[0231] The present invention provides a cell membrane formed by IMRC cells and the extracellular matrix and active factors secreted by them. Compared with the mesenchymal stem cell membrane, the IMRC cell membrane highly expresses immune regulation-related factors, nutritional factors and extracellular matrix-related proteins, secretes more types of active factors, and lowly expresses pro-inflammatory factors, and has a stronger immune regulation ability; the IMRC cell membrane also has better mechanical properties, and the fibers are denser and more uniform. The IMRC cell membrane provided by the present invention has important application value in the field of regenerative medicine.

[0232] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0233] Figure 1 .Light microscopic photos of cell membrane sheets cultured for different days.

[0234] Figure 2 .Day21 light microscopy image of cell membrane.

[0235] Figure 3 . Schematic diagram of cell membrane transfer. M cell membrane transfer can be achieved using PVDF membrane.

[0236] Figure 4 .Light microscopic photographs and HE staining images of cell membrane sheets cultured for a long time.

[0237] Figure 5 .Automated large-scale culture of cell sheets. Use the CellKeeper instrument to automatically culture and observe cell sheets.

[0238] Figure 6 . Schematic diagram of cell membrane culture and M cell hydrogel preparation.

[0239] Figure 7 .Light microscopic photograph of the cell membrane after decellularization.

[0240] Figure 8 .Identification of the thermosensitivity of IMRCs cell hydrogels.

[0241] Fig. 9 .Identification of viscosity and modulus of IMRCs cell hydrogels.

[0242] Fig.10 .Purification of IMRCs cell hydrogels.

[0243] Fig.11 .Electron microscopy detection of IMRCs cell hydrogel (10mg / ml).

[0244] Fig.12 .Verification of the in vivo thermosensitivity of IMRCs cell hydrogel.

[0245] Fig.13 . Determination of the yield of cell membrane hydrogel. The cell membrane is decellularized and other treatments are performed to prepare the hydrogel, and its yield is calculated.

[0246] Fig.14 . Detection of the expression of genes related to extracellular matrix synthesis and cell proliferation in cell membrane sheets.

[0247] Fig.15 . Detection of expression of inflammation and immune regulation related genes in cell membranes.

[0248] Fig.16 .PCA analysis of cell membrane sheet transcriptome sequencing.

[0249] Fig.17 .GO analysis of cell membrane transcriptome sequencing.

[0250] Fig.18 . Detection of expression of extracellular matrix and inflammation-related genes in cell membrane sheets.

[0251] Fig.19 . Schematic diagram of the mechanical properties test of cell membrane.

[0252] Fig. 20 .Cell membrane mechanical properties test diagram.

[0253] Fig.21 .Cell membrane sheet tensile test stress and strain.

[0254] Fig. 22 .Mechanical properties test of cell membrane.

[0255] Fig.23 .Detection of Young's modulus of cell membrane.

[0256] Fig.24 .Electron microscopic photograph of the cell membrane after decellularization.

[0257] Fig.25 .Immunofluorescence identification of extracellular matrix components in cell membrane sheets. .

[0258] Fig.26 .Immunofluorescence identification of extracellular matrix components of cells.

[0259] Fig. 27 :The Bio-Plex 200 suspension chip system was used to detect the factor secretion of cell membrane sheets. (A) Detection of immune regulation-related factors, nutritional factors, and pro-inflammatory factors in cell membrane sheets; (B) Expression of pro-inflammatory factors; (C) Expression of immune regulation and nutritional factors.

[0260] Figures 28A-28B .Protein profile identification of cell membrane sheets after decellularization.

[0261] Fig.29 .Mass spectrometry composition analysis of cell membrane sheets.

[0262] Fig.30 .Identification of components in cell membrane sheets.

[0263] Fig.31 .IMRC cell hydrogel promotes the proliferation of IMRC cells. A. Light microscope photos of IMRC cells seeded on hydrogels for different days. B. Compared with ordinary culture plates, IMRC cell hydrogels can significantly promote the proliferation of IMRC cells. C. Identification of surface markers of IMRC cells after hydrogel culture.

[0264] Fig.32 .IMRC cell hydrogel promotes the migration of GFP-IMRC cells.

[0265] Fig.33 .IMRC cell hydrogel can encapsulate GFP-IMRC cells and promote the proliferation and extension of GFP-IMRC cells.

[0266] Fig.34 .IMRC cell hydrogel can promote HUVEC angiogenesis in vitro.

[0267] Fig.35. Treatment of rat corneal alkali burns by non-decellularized IMRC cell sheets. A. Schematic diagram of rat corneal alkali burn modeling. B. Light microscope photography of rat corneas at different days after IMRC cell sheet treatment. C. Scoring of rat corneal clarity. DF. Results of rat corneal HE staining and immunohistochemistry.

[0268] Fig.36 .Schematic diagram of IMRC hydrogel in vivo transplantation to treat intrauterine adhesions in rats.

[0269] Fig.37 .Image of IMRC hydrogel transplantation in vivo to treat rat intrauterine adhesions.

[0270] Fig.38 .IMRC hydrogel in vivo transplantation to treat rat intrauterine adhesions, light microscopic photo of the sample collection.

[0271] Fig.39 Analysis of uterine tissue sections after IMRC hydrogel treatment of rat intrauterine adhesions.

[0272] Sequence information

[0273]

[0274] Example

[0275] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.

[0276] Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present application. The experimental methods in the embodiments are conventional methods unless otherwise specified. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0277] Example 1: Preparation of IMRC cells

[0278] 1.1 Generation of embryoid bodies (EBs)

[0279] Human embryonic stem cells (CB0019, National Stem Cell Resource Bank) were cultured in a low-attachment culture dish (Corning: Catalog No. 3262) using EB culture medium and cultured in a 37° C. incubator to form EB spheres.

[0280] Preparation of EB culture medium: Add 10% (v / v) KOSR, 1% (v / v) NEAA (i.e., 0.1 mM), 1% (v / v) GlutaMAX (i.e., 2 mM), 8 ng / mL bFGF and 0.1% (v / v) β-mercaptoethanol to KO-DMEM.

[0281] 1.2 EB sphere adherence culture

[0282] Culture the EB spheres obtained in step 1.1 in a 6-well plate coated with vitronectin using IMRC culture medium. Change the medium every day until about 14 days, and then perform IMRC subculture. The subculture operation can be repeated, for example, to the fifth generation for subsequent operations or cryopreserved using Cryostor CS10.

[0283] Preparation of IMRC culture medium: Add 1% (v / v) Ultroser G, 5% (v / v) KOSR, 1% (v / v) NEAA, 1% (v / v) GlutaMAX, 5 μg / mL ascorbic acid, 5 ng / mL bFGF, and 5 ng / mL TGFβ to α-MEM.

[0284] Example 2: Preparation of cell membrane sheets

[0285] IMRC cells were passaged in IMRC medium after reaching approximately 80% confluence. To prepare cell sheets, a total of 2 × 10 5 IMRC cells were seeded onto a collagen I peptide-coated cell culture surface (BD Biosciences, 356270) at a cell density of 2×10 4 / cm 2 All cultures were maintained in a humidified incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C with 5% carbon dioxide and atmospheric oxygen. IMRC medium consisted of α-MEM supplemented with 5% KOSR, 1% Ultroser G, 1× L-glutamine, 1× NEAA, and 5 ng / mL bFGF and 5 ng / mL TGF-β. On days 3 to 21, 40 μmol / L vitamin C (Sigma-Aldrich, St Louis, MO, USA) was added to the culture medium.

[0286] As a control, primary umbilical cord mesenchymal stem cells (UCMSC) were used to prepare UCMSC cell membranes, wherein UCMSC medium was used, which consisted of α-MEM supplemented with 5% KOSR, 1% Ultroser G, 1×L-glutamine, 1×NEAA and 5ng / mL bFGF. The medium was changed every day, and 40μmol / L vitamin C (Sigma-Aldrich, St Louis, MO, USA) was added to the medium from day 3 to day 21.

[0287] Light microscopic photos of cell membrane sheets at different culture days Figure 1 As shown in Figure 2, IMRC cells can be seen growing on the wall in a fibrous, uniform morphology. On day 21, the light microscopic image of the entire cell membrane sheet is as follows: Figure 2 As shown, the IMRC cell membrane sheet has a dense structure and a smooth surface. In contrast, the UCMSC cell membrane sheet has poor integrity and is obviously broken, wrinkled, cracked, and uneven. In addition, the IMRC cell membrane sheet is thicker than the UCMSC cell membrane sheet.

[0288] In addition, the transfer of M cell membranes can be achieved using PVDF membranes. Figure 3 Specifically, (1) discard the culture medium of the IMRCs cell membrane sheet (IMRC-CSs); (2) cut the PVDF membrane into the same size as the 6-well plate; (3) use tweezers to transfer the PVDF membrane to the IMRC-CSs from which the culture medium has been discarded, remove the air, and make the PVDF membrane and the cell membrane sheet fit together; (4) use tweezers to clamp a section of the PVDF membrane and gently peel it off, so that the IMRC-CSs and the PVDF membrane are fitted together and can be transferred; (5) transfer to the target area, add PBS buffer solution on the PVDF membrane, separate the membrane from the IMRC-CSs, and complete the transfer of the cell membrane sheet.

[0289] In addition, the inventors unexpectedly discovered that Figure 4 As shown in the figure, IMRC cell sheets can be cultured for a long time to obtain a membrane sheet with a thickness of 100 μm. In contrast, UCMSC cell sheets have obvious fragmentation, wrinkles and cracks after 21 days of culture, so UCMSC cell sheets cannot be cultured for a long time to obtain a cell sheet with a higher thickness.

[0290] In addition, 1×10 3 / cm 2 Up to 1×10 6 / cm 2Cell membranes can be prepared at any cell density. Cell membranes can be prepared at a vitamin C concentration of 1-100μmol / L, or by replacing a derivative of Vc, such as using L-ascorbic acid 2-phosphate at a concentration of 10μmol / L on the 1st to 2nd day of culture, or using L-ascorbic acid 2-phosphate at a concentration of 10μmol / L on the 3rd to 21st day. Cell membranes can also be prepared by coating the surface of the culture dish with collagen and collagen derivatives, gelatin and gelatin derivatives, laminin and its derivatives, fibronectin and its derivatives, and fibronectin and its derivatives.

[0291] In addition, the CellKeeper instrument was used to automate the culture of IMRC cells to prepare cell membranes. Figure 5 shown.

[0292] In the following examples, unless otherwise specified, the cell membranes tested were all membranes cultured for 21 days.

[0293] Example 3: Preparation of decellularized matrix materials

[0294] The cell membrane sheet can be decellularized to obtain a cell-free membrane sheet, and further digested to obtain a cell-free hydrogel. Figure 6 shown.

[0295] Decellularization: Decellularize the cell membrane with 1% Triton-x 100 + 20mM NH3H2O ​​or 0.1% SDS at 37℃ for 15min. Rinse twice with PBS, 15min / time. To remove DNA, add 100IU / ml DNase and treat for 2h. Rinse twice with PBS, 15min / time.

[0296] DNA residual detection: Take a small part of the cell membrane before and after decellularization as a sample, use a DNA extraction kit (DNeasy Blood and Tissue Kit, Qiagen) to extract DNA, and detect and read the DNA residual concentration on Nanodrop.

[0297] Preparation of hydrogel: Cut the decellularized cell membrane into pieces, dissolve with acetic acid and pepsin for 48 hours, dialyze for 48 hours, freeze-dry, weigh and dissolve with PBS solution at pH=8 to prepare a 10 mg / ml hydrogel.

[0298] Light microscopic photograph of the cell membrane after decellularization Figure 7 As shown in the figure, the IMRC cell sheet is smoother after decellularization, while the UCMSC cell sheet has more dead cell aggregates.

[0299] The results of the thermosensitivity test of IMRC cell hydrogels are shown in Figure 8 As shown. The IMRC cell membrane was decellularized with Triton-X100 and then dissolved with acetic acid and pepsin, and then dialyzed and freeze-dried. Under different pH conditions, it was placed at 37 degrees Celsius for gelation identification. The results showed that the IMRC cell hydrogel can gel well at pH 7-9, which shows that the IMRC cell hydrogel has good temperature sensitivity.

[0300] Rheological characterization of mechanical properties: The rheological characterization of IMRCs hydrogels was carried out using a MCR 302 (Anton Paar, Austria) parallel plate rheometer. By measuring the storage (G′) and loss modulus (G″) of the IMRCs hydrogel pregel, a temperature ramp oscillation test was performed to evaluate its gelation kinetics. The neutralized IMRCs hydrogel pregel samples were loaded into Peltier plates with a volume of 200 μL. After determining its linear viscoelastic range by amplitude scanning, we used an amplitude of 1% as the set amplitude for the temperature scan. For the temperature scan (1%, 0.5%, 0.25% IMRCs hydrogel), the oscillation frequency was 1s -1 , the temperature range is 0℃-40℃, the slope is 0.5℃ min -1 . Statistics were obtained and plotted using Origin 2021b, including power law fitting.

[0301] The viscosity and modulus of IMRC cell hydrogels were determined as follows: Fig. 9 As shown in the figure, the viscosity of IMRC cell hydrogel increases with the increase of concentration, and at 1%, M-ECM (10 mg / mL) begins to solidify at 23.7°C, which proves that M cell hydrogel has good temperature sensitivity, and the modulus gradually increases with the increase of concentration.

[0302] The purification results of IMRC cell hydrogels are shown in Fig.10 As shown. A. IMRC cell hydrogels were treated with different concentrations of NaCl and centrifuged. B. Identification of protein content of IMRC cell hydrogels after treatment with different concentrations of NaCl. With the increase of NaCl concentration, the solubility of M cell hydrogels reached the maximum when treated with 900mM NaCl. C. After NaCl treatment, IMRC cell hydrogels still have good temperature sensitivity and can form gels.

[0303] Scanning electron microscopy of IMRC cell hydrogel (10 mg / ml) Fig.11 As shown in Figure 2, the IMRC cell hydrogel is a porous network structure after gelation.

[0304] Verification of the thermosensitivity of IMRC cell hydrogels in vivo Fig.12A. 100ul of IMRC-gel was injected subcutaneously into SD rats and removed after 10 minutes; B. The IMRC-gel after removal was in a jelly-like state, indicating that IMRC-gel is an injectable and thermosensitive hydrogel.

[0305] The yield test results of cell membrane hydrogel are as follows Fig.13 As shown, the yield of IMRC cell hydrogels was significantly better than that of UCMSC membranes.

[0306] Example 4: Identification of gene expression characteristics of cell membrane sheets

[0307] Total RNA was extracted from the prepared cell membrane sheet, and then RNA-seq transcriptome sequencing or Real-time PCR quantification was performed to identify its gene expression characteristics. The primers are shown in SEQ ID NOs: 1-30.

[0308] like Fig.14 As shown in the figure, RNA-seq data showed that the genes upregulated in IMRC cell sheets compared with UCMSC cell sheets were clustered into pathways related to extracellular matrix synthesis and cell proliferation (A); the genes upregulated in IMRC compared with UCMSC included: ELN, FN1, COL1A1, COL1A2, TNC, POSTN, COL4A1, COL4A2 (B); mRNA quantification results showed that the expression of extracellular matrix-related genes COL1A1, COL1A2, FN1, ELN, COL4A1, COL4A2, LAMC1, TNC, and POSTN in IMRC cell sheets was significantly higher than that in UCMSC cell sheets (C). In summary, the secretion of extracellular matrix in IMRC cell sheets was significantly higher than that in UCMSC.

[0309] like Fig.15 As shown in the figure, RNA-seq data showed that the genes upregulated in UCMSC cell sheets were clustered into inflammation-related pathways compared with IMRC cell sheets (A); the genes downregulated by IMRC compared with UCMSC included IL1B, CCL2, IL1A, and IL6 (B); mRNA quantification results showed that there were significant differences in the expression of inflammation- and immune-regulation-related genes between IMRC cell sheets and UCMSC cell sheets (C). In summary, the expression of inflammatory genes in IMRC cell sheets was lower, and the expression of immune-regulation genes was higher, and IMRC cell sheets had stronger immune-regulation capabilities than UCMSC.

[0310] The mRNA quantification results of representative genes are shown in the following table.

[0311] Table 1: mRNA quantification results of representative genes

[0312] Gene IMRC Cell Sheets UCMSC cell membrane Change multiple FN 10.79 1.528 7.06 ELN 11139 84.81 131.34 POSTN 342.3 2.597 131.81 COL1A1 9.824 0.9870 9.95 COL1A2 12.85 0.9895 12.99 COL4A1 4.925 0.7303 6.74 TNC 48.93 2.315 21.14 COL4A2 7.243 0.7589 9.54 LAMC1 0.7340 0.5696 1.29 CXCL12 1.453 0.9706 1.50 IL6 0.03095 3.551 0.01 IL1α 0.07279 0.4485 0.16 IL1β 0.0006423 0.004602 0.14

[0313] PCA analysis of transcriptome sequencing of cell membrane sheets Fig.16 As shown, there are significant differences in the transcriptomes between IMRC cell sheets and UCMSC cell sheets.

[0314] GO analysis of transcriptome sequencing of cell membrane sheets Fig.17 As shown, the genes expressed higher in IMRC cell sheets than in UCMSCs on day 21 were clustered into signaling pathways related to extracellular matrix assembly and vascular development; the genes expressed higher in UCMSCs than in IMRCs on day 21 were clustered into signaling pathways related to inflammation.

[0315] The expression of extracellular matrix and inflammation-related genes in the cell membrane Fig.18 As shown, compared with UCMSC, IMRC cell sheets highly expressed extracellular matrix-related genes, including FN1, COL1A1, COL1A2, TNC, POSTN, ECM2, ELN, COL6A3, and COL6A2, and lowly expressed pro-inflammatory-related genes, including IL1A, IL1B, and IL6.

[0316] Example 5: Determination of mechanical properties of cell membrane sheets

[0317] AFM tensile testing:

[0318] AFM (Nanowizard4, Bruker, USA) was used to test the elastic modulus of the cell membrane, which has been widely used for the characterization of biomaterials and cell properties. AFM measurements were performed using a silicon nitride cantilever with a nominal spring constant of 0.12 N / m (NP-O10, Nanoworld, USA) and a 30 μm diameter silicon bead (Thermo). Each sample was measured at 5 points, and 8 force curves were collected at each end. Applied mechanics and Hertz models can be used to fit and calculate data with the spherical indenter involved in the indentation. The data from the load portion of the load-displacement curve was used to determine the Young's modulus using a fit of all data points from the contact point to the maximum load point.

[0319] Uniaxial tensile test:

[0320] IMRC and UCMSC cell membrane samples were tested. The type of testing equipment used was an Instron 5943 tensile testing machine (Instron, Canton, MA, USA). Clamps were used to fix the two ends of the sample. We measured the width W and thickness T of the cell membrane sample. Before starting the experimental measurement, we measured the initial length L of the sample between the clamps. The load was applied at a rate of 10 mm / min until the sample broke. We recorded the change in force F and sample length ΔL during the experiment. Then, we obtained the stress σ=F / A during the experiment, where A is the cross-sectional area of ​​the sample. The calculation formula for the cell sheet is as follows. A=WT. The calculation formula for strain is as follows. ε=ΔL / L0. The initial linear slope of the stress-strain curve was used to calculate the tensile elastic modulus (Young's modulus, E) (from 10% to 30% strain). All these factors can be combined into an equation for F:

[0321] Schematic diagram of the mechanical properties test of cell membrane Fig.19 As shown, the IMRC cell sheets and UCMSC cell sheets were tested by instron and AFM on day 21.

[0322] The mechanical properties test of cell membrane is shown in the figure Fig. 20 As shown, the IMRC cell membrane sheet and the UCMSC cell membrane sheet were subjected to instron tensile testing on day 21. The IMRC cell membrane sheet can withstand greater tensile forces.

[0323] The stress-strain results of the cell membrane tensile test are as follows Fig.21 The mechanical properties test results of the cell membrane are shown in Fig. 22 The results showed that when the instron test was performed on day 21, the IMRC cell membrane had significant differences in UTF, UTS, and elastic modulus compared with UCMSC, indicating that the IMRC cell membrane had stronger mechanical properties than the UCMSC cell membrane.

[0324] The test results of Young's modulus of cell membrane are as follows: Fig.23 As shown, compared with the UCMSC cell sheet, the IMRC cell sheet has a larger Young's modulus, indicating that the IMRC cell sheet has stronger mechanical properties.

[0325] Electron microscopic photograph of the cell membrane after decellularization Fig.24 As shown, compared with UCMSC, the fiber diameter of IMRC cell membrane sheet is more uniform and the fiber density is greater.

[0326] Example 6: Protein secretion detection of cell membrane sheets

[0327] The cell membrane was immunofluorescently stained and then observed and collected under a laser confocal microscope. The antibodies used included: collagen I (Abcam, Cambridge, MA, USA; Ab34710), 1:150 rabbit anti-collagen IV (Abcam, Cambridge, MA, USA; Ab6586), 1:150 rabbit anti-laminin (GeneTex, Irvine, CA, USA; GTX27463), and 1:150 rabbit anti-fibronectin (GeneTex, Irvine, CA, USA; GTX112794).

[0328] The immunofluorescence identification results of cell membrane sheets and cells are shown in Fig.25 and Fig.26 As shown, the extracellular matrix components of IMRC cell sheets were expressed at a higher level than those of UCMSC.

[0329] The cell membrane was used to detect the secretion of factors. The culture supernatant of the IMRC cell membrane and UCMSC cell membrane was harvested on day 21, and the secretion of factors was detected using the Bio-Plex 200 suspension chip system. The results are shown in Fig. 27 As shown, after 21 days of culture, the LIF content of IMRC cell membrane was 190.19pg / mL, which was 437 times higher than that of UCMSC cell membrane, and the HGF content was 111.86pg / mL, which was 1.25 times higher than that of UCMSC cell membrane. Compared with UCMSC cell membrane, IMRCs cell membrane expressed higher levels of immune regulation-related factors and nutritional factors, and lower levels of pro-inflammatory factors. Compared with UCMSCs cell membrane, IMRCs cell membrane is more conducive to clinical application and has better therapeutic effects.

[0330] LC-MS identification was performed on the matrix gel after decellularization of the cell membrane sheet. In brief, the matrix gel was used as the loading sample for SDS-PAGE; the corresponding gel was obtained after SDS-PAGE gel electrophoresis experiment, and the corresponding area of ​​the band was cut out after staining, and LC-MS mass spectrometry identification was performed after processing. Mass spectrometry analysis (DDA mode) was performed, and each scanning cycle had a full MS scan and included 15 subsequent MS / MS scans. (HCD collision energy: 28; quadrupole screening window 1.6Da; dynamic exclusion time: 35s; data comparison reference UniProt-Homo database (trypsin; maximum missed cleavage site: 2; fixed modification: Carbamidomethyl (C); variable modification Oxidation (M), Dioxidation (W), Deamidated (NQ), Acetyl (Protein N-MS tolerance: ±10ppm MS / MS tolerance: ±0.6Da, protein score CI%>95% was defined as successful identification).

[0331] The protein spectrum identification results after decellularization of the cell membrane sheet are as follows Figures 28A-28B As shown in the figure, there are more types of extracellular matrix-related proteins and factors in IMRCs. Compared with UCMSCs cell membrane sheets, the proteins with increased content in the extracellular matrix of IMRCs include: COL15A1, COL8A1, EFEMP2, FBLN5, MFAP2, MXRA5, PCOLCE, THBS2, LOXL2, TIMP1, CLEC2D, HPX, BGN, and GDF15.

[0332] The results of mass spectrometry analysis of cell membrane after decellularization are as follows Fig.29 As shown in the figure, the variety of extracellular matrix in IMRC membrane after decellularization is higher than that in UCMSC membrane. The main components in IMRCs and UCMSCs cell membranes are FN1 and COL1A1, and in IMRCs cell membranes, FN1 ranks the highest.

[0333] The protein content, collagen and GAG content of IMRCs and UCMSCs cell membranes after decellularization were identified. The total protein content was determined using the BCA experimental method (using thermo 23252), the collagen content was determined using the Sircol dye reagent, and the GAG ​​content was determined using the Blyscan staining reagent. Fig.30 As shown, the results showed that the content of extracellular matrix in IMRCs cells was higher than that in UCMSCs.

[0334] Example 7: Hydrogels for promoting proliferation and migration of IMRC cells

[0335] Experimental methods:

[0336] (1) Plating: IMRC hydrogel (M-Mgel) or filtered hydrogel (filtered with a 0.22 filter, M-Filtration) was plated at a concentration of 60 μg / ml, 1 mL per well of a 6-well plate, and placed in a 37°C incubator for 30 min. (2) Cell seeding: IMRCs were seeded into regular wells or wells coated with IMRC hydrogel at a cell density of 1x10 4 / cm 2 , culture for 3 days, changing the medium every day. (3) Cell digestion and counting; and identification of surface markers.

[0337] result:

[0338] like Fig.31 As shown in the figure, compared with ordinary culture plates, the IMRC hydrogel coating can significantly promote the proliferation of IMRC cells, while the expression of cell surface markers does not change. The above data show that IMRC hydrogel can promote the proliferation of IMRC cells and keep the properties of cells unchanged.

[0339] like Fig.32 As shown, compared with the ordinary culture plate and the collagen-coated group, the migration of GFP-IMRC cells can be significantly promoted after coating with IMRC hydrogel.

[0340] like Fig.33 As shown, IMRC hydrogel can encapsulate GFP-IMRC cells and promote the proliferation and extension of GFP-M cells.

[0341] Example 8: Hydrogels for promoting HUVEC angiogenesis in vitro

[0342] Experimental methods:

[0343] (1) Take 100 μL of IMRC hydrogel (5-10 mg / mL) or 100 μL of Collagen (5-10 mg / mL), add it to a 96-well plate, and place it in an incubator for 15 minutes. (2) Inoculate fluorescently labeled HUVECs into ordinary culture plates, culture plates coated with Collagen, and culture plates coated with IMRC hydrogel. (3) Under the living cell workstation, set the program to take pictures and record every half an hour for a total of 24 hours.

[0344] result:

[0345] like Fig.34 As shown, HUVEC cells were seeded into ordinary culture plates, collagen-coated culture plates, and IMRC hydrogel-coated culture plates. The results showed that IMRC hydrogel can promote the in vitro angiogenesis of HUVEC.

[0346] Example 9: Cell membrane sheet for treating corneal alkali burns

[0347] Rat corneal alkali burn model: 7-8 week old male SD rats (Vitamin Liva) were selected and anesthetized by inhalation of isoflurane. After soaking a 7 mm diameter filter paper in 1 M NaOH for 30 seconds, the excess NaOH was absorbed on the dry filter paper, and then transferred to the right cornea of ​​the rat for 30 seconds, and then rinsed with 50 mL of saline. The IMRCs or UCMSCs cell membrane was placed in the damaged cornea, and then the eyelids were sutured with 5-0 silk thread. Photographs were taken on Day 3, Day 7, and Day 21, and samples were taken for pathological section analysis.

[0348] The results are as follows Fig.35 As shown in the figure, IMRC patch treatment can reduce the infiltration of macrophages on day 3, and the expression of CD31 and α-SMA in the cornea is significantly lower than that in the model group on day 21. The scores of the IMRC patch treatment group are significantly different from those of the NaOH group, indicating that IMRC patch can effectively treat corneal alkali burns in rats.

[0349] Example 10: Hydrogel for treating intrauterine adhesions

[0350] Rat intrauterine adhesion modeling: A rat intrauterine adhesion model was established by injecting anhydrous ethanol into the uterus. Female SD rats aged 7-8 weeks (Vitamin Liva) were selected, and all rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital (0.3 ml / 100 g), the abdomen was shaved, and the uterine horns were exposed through an abdominal incision. The proximal and distal parts of the uterus were then gently clamped with two vascular clamps, and then 95% ethanol was injected into the right uterine cavity for 5 minutes. The damaged area was washed three times with saline to further remove the residual ethanol, and then the vascular clamp was released. One week after animal modeling, the animals in the experimental group underwent surgery again, and the proximal and distal parts of the damaged uterus were gently clamped with two vascular clamps, and saline, collagen, and IMRCs hydrogel were injected into the uterus at the same time. After three estrus cycles after the injection of the hydrogel, the rats were euthanized, and the uterine tissue was removed and sliced ​​for downstream analysis.

[0351] Fig.36 Schematic diagram of in vivo transplantation of IMRC hydrogel to treat intrauterine adhesions in rats is shown.

[0352] like Fig.37 As shown in Figure 2, after IMRCs hydrogel was transplanted, it could be clearly gelled in the uterine cavity. Fig.38 As shown in the figure, there were no obvious blisters in the IMRCs hydrogel treatment group, while there were obvious blisters in the alcohol and collagen groups, indicating that IMRCs hydrogel has a good therapeutic effect on intrauterine adhesions. Fig.39As shown in the data, after IMRC hydrogel treatment, the morphological structure of the rat uterus was intact, and the thickness of the endometrium, the number of blood vessels, and the number of glands were significantly different from those in the model group and the collagen group, indicating that IMRC hydrogel has a significant therapeutic effect on rat intrauterine adhesions; the proportion of uterine fibrosis in rats was significantly reduced, indicating that IMRC hydrogel can improve the fibrosis of rat intrauterine adhesions and has a good therapeutic effect.

[0353] Example 11: Preparation of chondrocyte membrane

[0354] After 7 days of IMRC cell membrane induction, the chondrocyte induction differentiation medium was replaced and the membrane induction culture was continued for 14 days. The medium was changed every day to make the cells in the cell membrane differentiate into chondrocytes. The chondrocyte membrane was harvested on the 21st day for in vitro property identification and in vivo functional verification. The chondrocyte membrane induction differentiation medium was prepared into chondrocyte differentiation medium according to the instructions of the human mesenchymal stem cell functional identification kit (human mesenchymal stem cell functional identification kit, catalog number: SC006).

[0355] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.

Claims

1. A cell membrane sheet formed by immune and matrix regulatory cells (IMRC) and the extracellular matrix secreted by them, wherein: The extracellular matrix at least comprises: COL15A1, COL8A1, EFEMP2, FBLN5, MFAP2, MXRA5, PCOLCE, THBS2, LOXL2, TIMP1, CLEC2D, HPX, BGN, GDF15; Preferably, the content of any of the above proteins is increased compared to that of primary mesenchymal stem cell membrane sheets (such as UCMSC cell membrane sheets); Preferably, the content of any of the above proteins is independently increased by at least about 1.2 times, at least about 1.5 times, at least about 1.8 times, at least about 2 times, at least about 2.5 times, at least about 3 times, at least about 3.5 times, at least about 4 times, at least about 4.5 times, at least about 5 times, at least about 5.5 times, at least about 6 times, at least about 6.5 times, at least about 7 times, at least about 7.5 times, at least about 8 times, at least about 8.5 times, at least about 9 times, at least about 9.5 times, at least about 10 times, at least about 15 times, at least about 20 times, at least about 25 times, at least about 30 times, at least about 35 times, at least about 40 times, at least about 45 times, at least about 50 times, at least about 60 times, at least about 70 times, at least about 80 times, at least about 90 times, at least about 100 times compared to the primary mesenchymal stem cell membrane (e.g., UCMSC cell membrane).

2. The cell membrane sheet according to claim 1, wherein Compared with a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet), the cell sheet has an FN expression level of at least about 5 times (e.g., about 6-8 times), an ELN expression level of at least about 100 times (e.g., about 120-140 times), and / or a POSTN expression level of at least about 100 times (e.g., about 120-140 times); Preferably, the expression level is the mRNA level.

3. The cell membrane of claim 2, which, compared with a primary mesenchymal stem cell membrane (e.g., a UCMSC cell membrane), further has one or more characteristics selected from the following: COL1A1 expression level is at least about 8 times (e.g., about 8 to 12 times); COL1A2 expression level is at least about 11 times (e.g., about 11 to 15 times); COL4A1 expression level is at least about 5 times (e.g., about 5 to 8 times); TNC expression level is at least about 20 times (e.g., about 20 to 24 times); COL4A2 expression level is at least about 8 times (e.g., about 8 to 12 times); LAMC1 expression level is at least about 1.1 times (e.g., about 1.1 to 1.4 times); and / or, CXCL12 expression level is at least about 1.2 times (e.g., about 1.2 to 1.6 times); Preferably, the expression level is the mRNA level.

4. The cell membrane sheet according to any one of claims 1 to 3, wherein The cell sheet secretes LIF and shows an increase of at least about 300 times (e.g., about 350-450 times) compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet); Preferably, the LIF content is at least about 100 pg / mL (e.g., about 180-200 pg / mL, about 185-195 pg / mL); Preferably, the cell sheet secretes HGF and shows an increase of at least about 1.1 times (e.g., about 1.2-1.4 times) compared to a primary mesenchymal stem cell sheet (e.g., a UCMSC cell sheet); Preferably, the HGF content is at least about 100 pg / mL (eg, about 110-120 pg / mL, about 110-115 pg / mL).

5. The cell membrane sheet according to any one of claims 1 to 4, wherein The pro-inflammatory factors secreted by the cell membrane are reduced compared with primary mesenchymal stem cell membranes (such as UCMSC cell membranes); Preferably, the pro-inflammatory factor is selected from IL6, IL1α, IL1β; Preferably, IL6 shows at least about 100-fold (eg, about 110-120-fold) reduction compared to a primary mesenchymal stem cell sheet (eg, a UCMSC cell sheet); Preferably, IL1α shows at least about 5-fold (eg, about 5-7-fold) reduction compared to a primary mesenchymal stem cell sheet (eg, a UCMSC cell sheet); Preferably, IL1β shows at least about 6-fold (eg, about 6-8-fold) reduction compared to a primary mesenchymal stem cell sheet (eg, a UCMSC cell sheet); Preferably, the expression level is the mRNA level.

6. The cell membrane sheet according to any one of claims 1 to 5, wherein The fiber diameter of the extracellular matrix is ​​less than 0.5 μm, such as 0.2-0.5 μm, 0.2-0.4 μm, 0.3-0.4 μm; and / or the fiber density is 12-16 fibers / 25 μm 2 .

7. The cell membrane sheet according to any one of claims 1 to 6, wherein The cell membrane sheet has a Young's modulus of at least 500 Pa, such as at least 800 Pa, at least 1000 Pa, at least 2000 Pa, at least 3000 Pa or at least 3500 Pa.

8. The cell membrane sheet according to any one of claims 1 to 7, wherein The thickness of the cell membrane sheet is at least 10 μm, such as at least 30 μm, at least 50 μm, at least 60 μm, at least 70 μm, at least 80 μm, at least 90 μm, or at least 100 μm.

9. A method for preparing a cell membrane sheet, comprising: IMRC cells are cultured in a medium containing vitamin C or its derivatives (eg, ascorbic acid 2-glucoside, ascorbyl glucoside, or isoascorbic acid) to obtain cell sheets.

10. The method of claim 9, wherein: IMRC cells were seeded in culture vessels coated with matrix; Preferably, the coating matrix is ​​selected from collagen, gelatin, laminin, fibronectin, or derivatives thereof.

11. The method according to claim 9 or 10, wherein The seeding density of the IMRC cells was 1 × 10 3 / cm 2 ~1×10 6 / cm 2 ; For example, 1×10 3 / cm 2 ~1×10 5 / cm 2 , 1×10 3 / cm 2 ~5×10 4 / cm 2 , 5×10 3 / cm 2 ~1×10 5 / cm 2 , 5×10 3 / cm 2 ~5×10 4 / cm 2 , for example 2×10 4 / cm 2 .

12. The method according to any one of claims 9 to 11, wherein The content of vitamin C or its derivatives is 1-100 μmol / L, for example, 10-100 μmol / L, 10-80 μmol / L, 10-60 μmol / L, 10-50 μmol / L.

13. The method according to any one of claims 9 to 12, wherein: The culture medium is a basal medium supplemented with the following substances: one or more serum or serum replacements, one or more non-essential amino acids, glutamine or a stabilized dipeptide of L-alanyl-L-glutamine, and one or more growth factors; Preferably, the one or more sera or serum replacements comprise KOSR and Ultroser G; Preferably, the non-essential amino acid is selected from glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine and combinations thereof; for example, NEAA; Preferably, the basal culture medium is selected from α-MEM, MEM, DMEM, high-glucose DMEM, KO-DMEM, and any combination thereof; Preferably, the one or more growth factors include bFGF and TGF-β; optionally, further include one or more selected from VEGF, EGF, or PDGF.

14. The method of claim 13, wherein: The medium is a basal medium supplemented with the following: 1-5% (v / v) Ultroser G, 5-30% (v / v) KOSR, 1-5 mM stabilized dipeptide of L-alanyl-L-glutamine, 1-100 ng / mL bFGF, 1-100 ng / mL TGFβ, and the following amino acids at a concentration of 0.1-0.5 mM each: glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine; Preferably, the basal culture medium is selected from KO-DMEM, KO-DMEM / F12, α-MEM, DMEM, DMEM / F12.

15. The method according to any one of claims 9 to 14, wherein Incubate for at least 1 day; For example, the culture is for at least 7 days, at least 14 days, such as 14 to 28 days or 14 to 21 days.

16. The method according to any one of claims 9 to 15, wherein The culture is carried out for at least 35 days, such as at least 42 days, such as 45 days.

17. A cell membrane sheet prepared by the method according to any one of claims 9 to 16.

18. A decellularized matrix material obtained by decellularizing the cell membrane sheet according to any one of claims 1 to 8 or the cell membrane sheet according to claim 17.

19. The decellularized matrix material according to claim 18, wherein: The decellularized matrix material is a membrane obtained by decellularizing the cell membrane according to any one of claims 1 to 8 or the cell membrane according to claim 17; Preferably, the decellularization treatment comprises physical methods (e.g., direct effects of temperature, pressure, electroporation and force), chemical methods (e.g., acids and alkalis, detergents, hypotonic and hypertonic solutions, alcohols and solvents), biological methods (such as enzymes, nucleases and chelators) or any combination thereof.

20. The decellularized matrix material according to claim 19, wherein The decellularized matrix material is a hydrogel obtained by decellularizing and digesting the cell membrane sheet according to any one of claims 1 to 8 or the cell membrane sheet according to claim 17; Preferably, the decellularization treatment comprises physical methods (e.g., direct effects of temperature, pressure, electroporation and force), chemical methods (e.g., acids and alkalis, detergents, hypotonic and hypertonic solutions, alcohols and solvents), biological methods (e.g., enzymes, nucleases and chelating agents) or any combination thereof; Preferably, the digestion treatment comprises the use of an acid (eg acetic acid or hydrochloric acid) and / or a digestive enzyme (eg pepsin or trypsin).

21. A method for preparing a cell-free matrix material, comprising: (1) Providing the cell membrane sheet according to any one of claims 1 to 8 or the cell membrane sheet according to claim 17; (2) performing a decellularization treatment on the cell membrane sheet; Preferably, the decellularization treatment comprises physical methods (e.g., direct effects of temperature, pressure, electroporation and force), chemical methods (e.g., acids and alkalis, detergents, hypotonic and hypertonic solutions, alcohols and solvents), biological methods (e.g., enzymes, nucleases and chelating agents) or any combination thereof; Preferably, the decellularization treatment comprises using a surfactant (e.g., a nonionic surfactant or an ionic surfactant, such as Triton-X 100, sodium dodecyl sulfate (SDS), sodium deoxycholate (SD)); Preferably, the decellularization treatment comprises freeze-thawing; Preferably, the decellularization treatment comprises using 1% Triton-X 100, such as 1% Triton-X 100 and 20 mM NH3·H2O; Preferably, the decellularization treatment comprises using 0.1% SDS; Preferably, the product obtained in step (2) is a decellularized membrane sheet.

22. The method of claim 21, wherein: The decellularized matrix material is a hydrogel, and the method further comprises digesting the decellularized product; Preferably, the digestion treatment comprises the use of an acid (e.g. acetic acid or hydrochloric acid) and / or a digestive enzyme (e.g. pepsin or trypsin); Preferably, the digestion treatment comprises using acetic acid and pepsin; Preferably, the digestion treatment further includes the steps of dialysis, freeze-drying and dissolution.

23. A composite cell sheet comprising IMRC cells and at least one cell selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, and retinal pigment epithelial cells.

24. The composite cell membrane sheet of claim 23, comprising at least two stacked cell membrane sheets, wherein at least one cell membrane sheet is the cell membrane sheet of any one of claims 1 to 8 or the cell membrane sheet of claim 17; Preferably, at least one layer of the cell membrane is a cell membrane formed by cells selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells and pericytes), corneal endothelium, and retinal pigment epithelial cells; Preferably, adhesive is included between each layer of the stacked cell membrane sheets; Preferably, the adhesive is made of a biocompatible material that can be degraded in the body; Preferably, the adhesive is the acellular matrix material according to any one of claims 18-20.

25. A method for preparing a composite cell membrane sheet, comprising: (1) providing a plurality of cell membrane sheets, at least one of which is the cell membrane sheet according to any one of claims 1 to 8 or the cell membrane sheet according to claim 17; (2) disposing an adhesive on one of the cell membrane sheets, and then laminating another cell membrane sheet thereon; (3) Repeating step (2); (4) obtaining a stacked product having a predetermined number of sheets; Preferably, at least one of the cell membrane sheets is a cell membrane sheet formed by cells selected from the group consisting of fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, and retinal pigment epithelial cells; Preferably, the adhesive is made of a material that is biocompatible and degradable in the human body; Preferably, the adhesive is the acellular matrix material according to any one of claims 18-20.

26. A composite cell membrane sheet comprising at least two stacked cell membrane sheets, wherein: The stacked cell membrane sheets contain an adhesive between each layer, and the adhesive is selected from the decellularized matrix material according to any one of claims 18 to 20; Preferably, the at least two layers of cell membranes are each independently formed by cells selected from the following: fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, retinal pigment epithelial cells; Preferably, the composite cell membrane sheet comprises a fibroblast membrane sheet and a keratinocyte membrane sheet.

27. A method for preparing a composite cell membrane sheet, comprising: (1) Providing multiple cell membrane sheets; (2) disposing an adhesive on one of the cell membrane sheets, and then stacking another cell membrane sheet thereon; wherein the adhesive is selected from the decellularized matrix material according to any one of claims 18 to 20; (3) Repeating step (2); (4) obtaining a stacked product having a predetermined number of sheets; Preferably, the plurality of cell membrane sheets are each independently formed by cells selected from the following: fibroblasts, keratinocytes, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, cardiac fibroblasts, vascular wall cells (e.g., smooth muscle cells, pericytes), corneal endothelium, retinal pigment epithelial cells; Preferably, the plurality of cell membrane sheets include fibroblast membrane sheets and keratinocyte membrane sheets.

28. Use of the decellularized matrix material according to any one of claims 18 to 20 as an adhesive; Preferably, the adhesive is used to prepare a cell membrane sheet; Preferably, the cell membrane sheet is a composite cell membrane sheet as described in claim 23, 24 or 26.

29. A cell sheet induced to differentiate, which is obtained by inducing differentiation of the cell sheet according to any one of claims 1 to 8 or the cell sheet according to claim 17; Preferably, the induced differentiated cell membrane is selected from ectoderm tissue membrane (e.g., neural crest cell membrane, nerve cell membrane, retinal pigment epithelial cell membrane, keratinocyte epithelial cell membrane), mesoderm tissue membrane (e.g., chondrocyte membrane, osteocyte membrane, adipocyte membrane, myocardial cell membrane, muscle cell membrane, vascular endothelial cell membrane, kidney cell membrane), endoderm tissue membrane (hepatocyte membrane, pancreatic β cell membrane, intestinal cell membrane, gastric cell membrane); Preferably, the cell sheet induced to differentiate is a chondrocyte sheet.

30. A pharmaceutical composition comprising the cell membrane sheet according to any one of claims 1 to 8 or the cell membrane sheet according to claim 17, the decellularized matrix material according to any one of claims 18 to 20, or the composite cell membrane sheet according to claim 23, 24 or 26, or the cell membrane sheet according to claim 29, and a pharmaceutically acceptable carrier and / or excipient.

31. Use of the cell membrane sheet according to any one of claims 1 to 8, the cell membrane sheet according to claim 17, the decellularized matrix material according to any one of claims 18 to 20, the composite cell membrane sheet according to claim 23, 24 or 26, the cell membrane sheet according to claim 29, or the pharmaceutical composition according to claim 30 in the preparation of a drug for regeneration or repair of tissues or organs.

32. Use of the cell membrane sheet according to any one of claims 1 to 8, the cell membrane sheet according to claim 17, the decellularized matrix material according to any one of claims 18 to 20, the composite cell membrane sheet according to claim 23, 24 or 26, the cell membrane sheet according to claim 29, or the pharmaceutical composition according to claim 30 in the preparation of a drug for treating tissue or organ damage; Preferably, the tissue or organ damage includes corneal damage (e.g. corneal alkali burn), skin damage (e.g. skin burn, skin scald, diabetic foot), heart disease (e.g. myocardial damage), bone damage (e.g. skull damage, bone defect), endometrial damage (e.g. intrauterine adhesion), meniscus damage, and / or muscle damage, periodontal damage (e.g. periodontitis), esophagus (e.g. esophageal mucosal damage), liver damage (e.g. cirrhosis), pancreatic disease (e.g. diabetes, pancreatitis), lung disease (e.g. lung damage, pulmonary fibrosis); Preferably, the cell sheet is induced to differentiate into osteoblasts or chondrocytes.

33. Use of the cell membrane sheet described in any one of claims 1 to 8 or the cell membrane sheet described in claim 17, the decellularized matrix material described in any one of claims 18 to 20, the composite cell membrane sheet described in claim 23, 24 or 26, or the cell membrane sheet described in claim 29, or the pharmaceutical composition described in claim 30 in the preparation of a medicament for cell, tissue or organ transplantation.

34. Use of the decellularized matrix material according to any one of claims 18 to 20 as a pharmaceutically acceptable carrier and / or excipient in a drug; Preferably, the drug comprises a nucleic acid drug, a small molecule drug, a protein drug, and / or a cell, tissue or organ transplant drug.

35. Use of the decellularized matrix material according to any one of claims 18 to 20 for cell culture (e.g., culture of pluripotent stem cells, differentiation of pluripotent stem cells), organoid culture, or 3D printing; Preferably, the acellular matrix material is used as ink for 3D printing; Preferably, the decellularized matrix material is used as a coating matrix for cell culture or organoid culture.

Citation Information

Cited By

  • Temperature-sensitive acellular matrix hydrogel as well as preparation method and application thereof

    CN121422308A

  • Thermosensitive decellularized matrix hydrogels, their preparation methods and applications

    CN121422308B